UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
14C
(Rule
14c-101)
SCHEDULE
14C INFORMATION
Information
Statement Pursuant to Section 14(c) of
the
Securities Exchange Act of 1934
Check
the appropriate box:
|
[X]
|
|
Preliminary
Information Statement
|
[ ]
|
|
Confidential,
for Use of the Commission Only (as permitted by Rule 14c-5(d)(2))
|
[ ]
|
|
Definitive
Information Statement
|
|
RESONATE
BLENDS, INC.
|
(Name
of Registrant As Specified In Its Charter)
Commission
File Number:
|
Payment
of Filing Fee (Check the appropriate box):
|
|
[ ]
|
|
No
fee required
|
|
|
|
[X]
|
|
Fee
computed on table below per Exchange Act Rules 14c-5(g) and 0-11
|
|
|
|
|
|
(1)
|
|
Title
of each class of securities to which transaction applies:
N/A
|
|
|
(2)
|
|
Aggregate
number of securities to which transaction applies:
N/A
|
|
|
(3)
|
|
Per
unit price or other underlying value of transaction computed pursuant to Exchange Act
Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it
was determined):
The
filing fee was determined by multiplying one-fiftieth of one percent by $331,032 (which is the estimated cash value of
the 4,822,029 shares of Resonate Blends, Inc. to be cancelled as consideration for the proposed sale, based upon the average
of the high and low prices reported on the OTCQB as of May 26, 2020
|
|
|
(4)
|
|
Proposed
maximum aggregate value of transaction:
$331,032
|
|
|
(5)
|
|
Total
fee paid:
$66,21
|
|
|
|
|
|
[ ]
|
|
Fee
paid previously with preliminary materials.
|
|
|
|
[ ]
|
|
Check
box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and
identify the filing for which the offsetting fee was paid previously. Identify the previous
filing by registration statement number, or the Form or Schedule and the date of its
filing.
|
|
|
|
|
|
(1)
|
|
Amount
Previously Paid:
|
|
|
(2)
|
|
Form,
Schedule or Registration Statement No.:
|
|
|
(3)
|
|
Filing
Party:
|
|
|
(4)
|
|
Date
Filed:
|
RESONATE
BLENDS, INC.
26565
Agoura Road, Suite 200
Calabasas,
CA 91302
571-888-0009
NOTICE
OF STOCKHOLDER ACTION BY WRITTEN CONSENT
To
the Stockholders of RESONATE BLENDS, INC.:
This
Information Statement is furnished to the stockholders of RESONATE BLENDS, INC., a Nevada corporation (the “Corporation”,
“RESONATE BLENDS, INC.”, “we”, “our”, or “us”), in
connection with our prior receipt of approval by a written consent, in lieu of a special meeting, of the holders of a majority
of our outstanding shares of common stock and Series C Preferred Stock, which represents a majority of our voting power to: authorize:
|
1)
|
the
sale of all of the shares and interests (the “Stock Sale’) of the Corporation’s wholly-owned subsidiary,
TEXTMUNICATION, INC., a California corporation (“Resonate Sub”), to an investment group led by our former
Chief Executive Officer and director, Wais Asefi (the “Asefi Group”), pursuant to a stock purchase agreement
(the “Purchase Agreement”) which was executed as of May 22, 2020, as described in the accompanying materials
(see attached Annex A); and
|
|
2)
|
Approval
of an amendment to the Corporation’s Articles of Incorporation (the “Amendment”) to increase the
total number of authorized shares of our Common Stock from one hundred million (100,000,000) shares to two hundred million
(200,000,000) shares (see attached Annex C).
|
The
Stock Sale and the Amendment are referred to as the “Corporate Actions.”
On
May 22, 2020, the Corporation obtained the approval of the Corporate Actions by written consent of several stockholders that together
are the record holders of 5,875,341 shares of the Corporation’s common stock, and 2,000,000 shares of Series C Preferred
Stock, representing approximately 63% of the voting power of the Corporation as of May 22, 2020. The Corporate Actions cannot
be effectuated until 20 days after the mailing of this Information Statement (the “Waiting Period”).
THE
CORPORATION IS NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED TO NOT SEND A PROXY. Because the written consent of the holders
of a majority of our voting power satisfies all applicable stockholder voting requirements, we are not asking for a proxy: please
do not send us one.
Only
holders of our common stock at the close of business on May 22, 2020 shall be given a copy of the Information Statement. The date
on which this Information Statement will be sent to stockholders will be on or about June 8, 2020.
The
accompanying Information Statement is for information purposes only. Please read it carefully.
The
Information Statement serves as notice of the foregoing action pursuant to the Written Consent in accordance with Section 78.320
of the Nevada Revised Statutes. The close of business on May 22, 2020 is the record date (the “Record Date”)
for the determination of the holders of our common stock entitled to receive the Information Statement. As of May 22, 2020, we
had 100,000,000 shares of our common stock authorized and 23,950,843 shares of our common stock outstanding and entitled to vote.
As of May 22, 2020, we had 2,000,000 shares of our Series C Preferred Stock designated and 2,000,000 shares of our Series C Preferred
Stock outstanding and entitled to vote. The Series C Preferred Stock has the power to vote 51% of the total vote.
By
Order of the Board of Directors
Very
truly yours,
RESONATE
BLENDS, INC.
|
|
|
|
By:
|
/s/
Geoff Selzer
|
|
Name:
|
Geoff
Selzer
|
|
Title:
|
Chief
Executive Officer
|
|
June
_____, 2020
TABLE
OF CONTENTS
AUTHORIZATION
BY THE BOARD OF DIRECTORS AND THE MAJORITY STOCKHOLDERS
Under
the Nevada Revised Statutes and the Company’s Bylaws, any action that can be taken at an annual or special meeting of stockholders
may be taken without a meeting, without prior notice and without a vote if the holders of outstanding stock having not less than
the minimum number of votes necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon
were present and voted consent to such action in writing. Accordingly, approval of the Corporate Actions required the affirmative
vote or written consent of a majority of the issued and outstanding shares of the Company’s Common Stock and Series C Preferred
Stock.
As
of May 22, 2020, the record date for the determination of stockholders entitled to notice of the approval of the Corporate Actions
and to receive a copy of this Information Statement (the “Record Date”), we had 23,950,843 shares of Common Stock
outstanding. Each holder of Common Stock is entitled to one vote per share of Common Stock held.
Also
on the Record Date, we also had 2,000,000 shares of Series C Preferred Stock outstanding. Under the Amended Certificate of Designation,
holders of our Series C Convertible Preferred Stock are entitled to vote on all shareholder matters with a vote equal to 51% of
the total vote of all classes of voting stock of our company. The rights of the holders of Series C Convertible Preferred Stock
are defined in the relevant Amended Certificate of Designation filed with the Nevada Secretary of State on May 16, 2019.
Our
Board of Directors unanimously adopted resolutions approving the Corporate Actions, subject to stockholder approval, by unanimous
written consent on May 22, 2020, we received the Written Consent from holders of our Common Stock representing 5,875,341 voting
shares and from the holder of our Series C Preferred Stock representing 24,950,000 shares, or approximately 63% of our outstanding
voting class, approving the Corporate Actions.
The
following table sets forth the name of the holder of the Common Stock and Series C Preferred Stock, the number of shares of Common
Stock and Series C Preferred Stock held by such holder, the total number of votes that such holder voted in favor of the Corporate
Actions and the percentage of the issued and outstanding voting equity of the Company that voted in favor thereof:
Name
of Voting Stockholder
|
|
Number
of Common Stock held
|
|
|
Number
of Series C Preferred Stock held
|
|
|
Number
of Votes held by such Voting Stockholder
|
|
|
Number
of Votes that Voted in Favor of the Amendment
|
|
|
Percentage
of the Voting Equity that Voted in Favor of the Amendment
|
|
Wais
Asefi
|
|
|
2,722,029
|
|
|
|
0
|
|
|
|
2,722,029
|
|
|
|
2,722,029
|
|
|
|
6%
|
|
Nick
Miniello
|
|
|
1,500,000
|
|
|
|
0
|
|
|
|
1,500,000
|
|
|
|
1,500,000
|
|
|
|
3%
|
|
Juleon
Asefi
|
|
|
500,000
|
|
|
|
0
|
|
|
|
500,000
|
|
|
|
500,000
|
|
|
|
1%
|
|
Curt
Byers
|
|
|
100,000
|
|
|
|
0
|
|
|
|
100,000
|
|
|
|
100,000
|
|
|
|
.2%
|
|
Geoffrey
Selzer
|
|
|
1,053,312
|
|
|
|
2,000,000
|
|
|
|
26,003,312
|
|
|
|
26,003,312
|
|
|
|
53%
|
|
Total
|
|
|
5,875,341
|
|
|
|
2,000,000
|
|
|
|
30,825,341
|
|
|
|
30,825,341
|
|
|
|
63%
|
|
Accordingly,
we have obtained all necessary corporate approval in connection with the Corporate Actions. We are not seeking written consent
from any other stockholder, and the other stockholders will not be given an opportunity to vote with respect to the actions described
in this Information Statement. This Information Statement is furnished solely for the purposes of advising stockholders of the
action approved by written consent and giving stockholders notice of the Corporate Actions as required by the Nevada Revised Statutes
and the Exchange Act.
QUESTIONS
AND ANSWERS REGARDING THE STOCK SALE
Q:
What are the material terms of the Purchase Agreement?
A:
RESONATE BLENDS, INC. and the Asefi Group, including Wais Asefi, our former Chief Executive Officer and director, have entered
into a Purchase Agreement, dated as of May 22, 2020, pursuant to which the Corporation has agreed to sell Resonate Sub to the
Asefi Group. Resonate Sub operates SMS business activities in California. RESONATE BLENDS, INC. will retain its operations in
cannabis based in Calabasas, California.
The
consideration for the sale of Resonate Blends, Inc. Sub consists of 4,822,029 shares of common stock of RESONATE BLENDS, INC.
that belong to Wais Asefi and other members of the Asefi Group, and which will be cancelled in the transaction. The 4,822,029
shares have a current market value of $337,542, based on our last sales price of $0.07 per share as of May 26, 2020.
The
Purchase Agreement contains customary representations, warranties and covenants made by RESONATE BLENDS, INC. and the Asefi Group,
including covenants relating to the conduct of their respective businesses between the date of signing of the Purchase Agreement
and the closing (the “Closing”), and customary non-solicitation provisions. The transactions contemplated by the Purchase
Agreement are also subject to customary conditions, including RESONATE BLENDS, INC.’ receipt of a Broker Opinion of Value
through Pricing Analysis from an independent firm and the approval of RESONATE BLENDS, INC.’ stockholders.
The
Purchase Agreement may be terminated by: (a) by mutual written consent of the parties; (b) by either party if the sale is not
consummated within two months following execution, subject to certain limitations; (c) by either party if a governmental entity
issues an order, decree or ruling or takes any other action, in any case having the effect of permanently restraining, enjoining
or otherwise prohibiting the sale, which order, decree, ruling or other action is final and non-appealable; (d) by either party
if the requisite approval of RESONATE BLENDS, INC. stockholders is not obtained, subject to certain limitations; (e) by RESONATE
BLENDS, INC., upon the Asefi Group’s breach of any representation, warranty, covenant or agreement, or if any representation
or warranty of the Asefi Group becomes untrue, in either case such that the conditions set forth in the Purchase Agreement would
not be satisfied as of the time of such breach or as of the time such representation or warranty becomes untrue, subject to cure
provisions; (f) by the Asefi Group, upon RESONATE BLENDS, INC.’ breach of any representation, warranty, covenant or agreement,
or if any representation or warranty of RESONATE BLENDS, INC. becomes untrue, in either case such that the conditions set forth
in the Purchase Agreement would not be satisfied as of the time of such breach or as of the time such representation or warranty
becomes untrue, subject to cure provisions; or (g) by RESONATE BLENDS, INC. if a material adverse effect with respect to the Asefi
Group occurs after the date of execution, subject to cure provisions.
Q:
Will RESONATE BLENDS, INC. have any potential liabilities in connection with the sale of Resonate Sub?
A:
RESONATE BLENDS, INC. does not expect to have any potential liabilities in connection with the sale of Resonate Sub. At the Closing,
all of the capital stock of Resonate Sub shall be transferred to the Asefi Group, which by operation of law shall include all
assets and liabilities of Resonate Sub existing on such date. Notwithstanding the foregoing, the Purchase Agreement requires indemnification
by RESONATE BLENDS, INC. and Wais Asefi and the Asefi Group for the breach of these representations and the covenants thereunder
and certain other matters as provided in the Agreement, as well as a full and unconditional general release of Wais Asefi.
Q:
Am I entitled to dissenters’ rights of appraisal?
A:
No. The Nevada Revised Statutes do not provide for dissenters’ rights of appraisal in asset sales transactions unless a
corporation’s certificate of incorporation expressly provides for those rights. Our Articles of Incorporation do not provide
for appraisal rights under these circumstances.
Q:
What factors did our board of directors consider in approving the Stock Sale transaction?
A:
In making its decision, our board of directors took into account, among other things: the overall business outlook of Resonate
Sub’s business; the Coronavirus pandemic and the uncertainty around the reopening of health clubs and the overall financial
impact to the health and fitness sector; the stated goal to develop RESONATE BLENDS, INC. into a pure play cannabis holding company;
the current and future competitive environment for Resonate Sub’s business – especially in a commoditized mobile marketing
sector; the uncertainty in the public market to raise the necessary capital to further develop RESONATE BLENDS, INC.’S business
and fulfill its business plan with Resonate Sub’s business remaining in the holding company and the financial analyses of
TransWorld Business Advisors which we had engaged as our consultant and the Broker Opinion of Value. As of the date of such opinion,
and based upon and subject to the various assumptions and qualifications set forth in its written opinion, we are convinced the
Stock Sale was fair to us from a financial point of view, as more fully described below under the section titled “Pricing
Analysis.” Further, in light of the technological and operational complexity of the software platform owned by Resonate
Sub, in the absence of Wais Asefi’s full time dedication to its operation, the software platform itself has limited value.
Q:
What corporate approvals were required for the Stock Sale?
A:
To approve the Stock Sale, the affirmative vote of a majority of directors and the affirmative vote of holders of stock entitling
them to exercise at least a majority of the voting power of our securities is required. Consents in favor of the Stock Sale have
already been received from our directors and stockholders holding a majority of the voting power of the Corporation.
Q:
Who will bear the cost of this Information Statement?
A:
RESONATE BLENDS, INC. shall bear the entire cost of this Information Statement, including mailing the Definitive Information Statement
to our stockholders.
Q:
What do I need to do now?
A:
We urge you to read this Information Statement carefully and to consider how the sale by RESONATE BLENDS, INC. of all of the shares
of Resonate Sub will affect your investment.
Q:
Who can help answer my questions?
A:
If you would like additional copies, without charge, of this Information Statement or if you have questions about the Stock Sale,
you should contact: Geoff Selzer, Chief Executive Officer of RESONATE BLENDS, INC., 26565 Agoura Road, Suite 200, Calabasas, California
91302, telephone 571-888-0009.
Q:
|
Will
the Stock Sale be a taxable transaction to me?
|
|
|
A:
|
Our
U.S. stockholders will not realize any gain or loss for U.S. federal income tax purposes as a result of the Stock Sale. See
“APPROVAL OF THE STOCK SALE-Material Federal Income Tax Consequences” beginning on page __.
|
Q:
|
When
is the Stock Sale expected to be completed?
|
|
|
A:
|
Pursuant
to the terms of the Purchase Agreement, the Stock Sale will be completed on the 20th day after the date of the
mailing of the Information Statement.
|
|
|
Q:
|
Are
there any risks related to the Stock Sale?
|
|
|
A:
|
Yes.
You should carefully read the section entitled “ APPROVAL OF THE STOCK SALE- Risk Factors Related to the Stock
Sale” beginning on page __.
|
APPROVAL
OF THE STOCK SALE
This
section of the Information Statement describes the material provisions of the Purchase Agreement but does not purport to describe
all the provisions of the Purchase Agreement. The following summary is qualified in its entirety by reference to the complete
text of the Purchase Agreement, which is included as Annex A to this Information Statement and is incorporated into this Information
Statement by reference. We urge you to read the full text of the Purchase Agreement because it is the legal document that governs
the Stock Sale. The Purchase Agreement has been included to provide you with information regarding its terms. It is not intended
to provide you with any other factual information about us. Such information can be found elsewhere in this Information Statement
and in the other public filings we make with the SEC, which are available without charge at www.sec.gov.
Purpose:
Our board of directors have unanimously adopted and holders of a majority of our outstanding shares of common stock and Series
C Preferred Stock have approved a resolution to authorize the board of directors to consummate the sale of Resonate Sub as provided
by the Purchase Agreement.
General
Background of Resonate Sub
We
were formed in October 1984 in the State of Georgia as “Brock Control Systems.” Founded by Richard T. Brock, we were
in the sales automation market and an early developer of enterprise customer management systems. We went public at the end of
March of 1993. In February of 1996, we changed our name to Brock International Inc., and in March of 1998, we again changed our
name to Firstwave Technologies, Inc.
In
2007, we deregistered our common stock in order to avoid the expenses of being a public company. The company reported briefly
on the OTC Disclosure & News Service in 2008 but not for long. We again changed our name to FSTWV, Inc.
On
October 28, 2013, we held a shareholder meeting to reincorporate our company in the State of Nevada and concurrently change our
name to Textmunication Holdings, Inc. We also voted to approve a 1 for 5 reverse split of our outstanding common stock.
Following
our shareholder meeting, on November 16, 2013, we entered into a Share Exchange Agreement (SEA) with Textmunication, Inc. a California
corporation and Wais Asefi (its sole shareholder), whereby we issued 65,640,207 new shares of common stock in exchange for 100%
of the issued and outstanding shares of Textmunication, Inc. and simultaneously the major shareholder of the company retired 1,128,041
post reverse shares (pre-split: 5,640,207) of our common stock to the company’s treasury. As a result of the SEA, we acquired
Textmunication, Inc. and have assumed its business operations.
Textmunication,
Inc., or Resonate Sub, was incorporated on May 13, 2010 under the laws of California.
Description
of Resonate Sub’s Business
Resonate
Sub is a developing player in the mobile marketing and loyalty industry, providing cutting-edge mobile marketing solutions, rewards
and loyalty to our clients. With a powerful yet intuitive suite of services, clients are able to reach more customers faster and
reward them for repeat business. We help clients reach their marketing and revenue goals by educating clients with the most effective
tools in mobile marketing, rewards, paperless redemption and loyalty.
In
the past 4 years, we have grown to over 765 clients and more than 950 different locations in the United States and Canada. We
have achieved this with an expanded focus on a variety of industries, including restaurants, retailers, entertainment venues and
other partnership opportunities. We have decided to focus our energy on the gym, health and fitness club market. However, we are
also working with Quick Service Restaurants (QSR), Beauty/Tanning salons, hospitality, entertainment, digital marketing and sporting
events.
Our
software platform provides a powerful nonintrusive and valued-added engagement tool capable of delivering more than one billion
SMS per month. CIO Review Magazine recognized Textmunication as one of the “Top 20 Most Promising Digital Marketing Solution
Providers” in its annual 2018 edition. We offer cutting-edge technology with solutions such as Rich Communication Services
(RCS).
We
have built an advanced “Communication Platform as a Service” (CPaaS) backbone enabling developers to add real-time
communication features in their own applications without needing to build backend infrastructure and interfaces. We are working
to develop “Messaging as a Platform” (MaaP). A MaaP platform combines advanced messaging with standardized interfaces
to plugins creating a richer experience for consumers, such as RCS. Textmunication expanded its White Label program allowing companies
of all sizes to implement an “out-of-the-box” solution “Powered by Textmunication”. In addition to White
Label, the company offers standalone Application Programming Interfaces or APIs, integrated API solutions and non-integrated services.
We
can produce a new API in 2-4 weeks for each new client. We now have 7 of the top 8 Health Club Management Software (CMS) companies
using our integrated SMS fitness solution. There is no other automated health and fitness solution offering a completed end-to-end
solution similar to ours. We now have access to more than 25,000 health clubs in North America and will focus on converting new
clubs to our solution in the next 12 months.
We
have incurred several legal bills assisting our Club Management Software (CMS) partners and health clubs with Telephone Consumer
Protection Act (“TCPA”) lawsuits. There is ambiguity to the current TCPA law and each state also has different provisions
making the law difficult to navigate. While we feel our solution protects our CMS partners and health club clients against TCPA
claims, we have had to support our partners with legal costs. We recently lost 43 clubs under one brand due to lawsuits against
the health club and legal threats to others. The recent Coronavirus closures of health clubs across the United States has also
put a significant financial strain on the texting business. Due to the uncertainty of when health clubs will reopen, our business
has been significantly impacted.
During
the years ended December 31, 2019 and 2018, Resonate Sub generated net revenues of $1,050,161 and $1,066,408, respectively. However,
due to the significant expenses associated with being a public company, we have been unable to generate sufficient revenue to
cover our expenses and have relied upon outside financing to support our business. For the years ended December 31, 2019 and 2018,
we incurred a net loss of $3,669,728 and $339,753, respectively. Although, we do believe that the Resonate Sub presents opportunities,
we do not believe that our current resources and infrastructure can support and successfully profit from such operations.
To
date, our primary sources of cash have been funds raised primarily from the sale of convertible notes and our equity securities
as well as revenue derived from operations.
We
incurred an accumulated deficit of $19,159,721 through December 31, 2019 and incurred negative cash flow from operations of $809,386
for the year ended December 31, 2019. We have spent, and need to continue to spend, substantial amounts in connection with implementing
our business strategy, including our planned product development effort and will be required to raise additional funding.
We
will need to generate additional revenue from operations and/or obtain additional financing to pursue our current business strategy,
repay our outstanding note obligations and take advantage of business opportunities that may arise. There can be no assurance
that we will be able to complete any such transactions on acceptable terms or otherwise and may have to significantly curtail
our operations.
At
December 31, 2019, we had cash of $53,139 and a negative working capital of $612,228, including a derivative liability of $262,712.
After eliminating the derivative liability our working capital deficit is $349,516.
Information
Regarding the Purchaser of Resonate Sub, Wais Asefi and the Asefi Group
The
Asefi Group includes the following persons, all of whom are shareholders of RESONATE BLENDS, INC. that will be cancelling their
respective shares in the Asset Sale.
Wais
Asefi: 2,722,029 shares of common stock
Nick
Miniello: 1,500,000 shares of common stock
Juleon
Asefi: 500,000 shares of common stock
Curt
Byers: 100,000 shares of common stock
Material
Terms of Purchase Agreement
RESONATE
BLENDS, INC. and the Asefi Group have entered into an Agreement, dated as of May 22, 2020, pursuant to which we have agreed to
sell Resonate Sub to the Asefi Group. RESONATE BLENDS, INC. will retain its cannabis. operations based in Calabasas, California.
The
consideration for the sale of Resonate Sub consists of 4,822,029 shares of common stock in RESONATE BLENDS, INC. held by Wais
Asefi and the other members of the Asefi Group, which shares will be cancelled and returned to treasury. The 4,822,029 shares
have a current market value of $337,542, based on our last sales price of $0.07 per share as of May 26, 2020.
The
Purchase Agreement contains customary representations, warranties and covenants made by RESONATE BLENDS, INC. and the Asefi Group,
including covenants relating to the conduct of their respective businesses between the date of signing of the Purchase Agreement
and the closing (the “Closing”), and customary non-solicitation provisions. The transactions contemplated by the Purchase
Agreement are also subject to customary conditions, including RESONATE BLENDS, INC.’ receipt of a Broker Opinion of Value
from an independent consulting firm and the approval of RESONATE BLENDS, INC.’ stockholders.
The
Purchase Agreement may be terminated by: (a) by mutual written consent of the parties; (b) by either party if the sale is not
consummated within two months following execution, subject to certain limitations; (c) by either party if a governmental entity
issues an order, decree or ruling or takes any other action, in any case having the effect of permanently restraining, enjoining
or otherwise prohibiting the sale, which order, decree, ruling or other action is final and non-appealable; (d) by either party
if the requisite approval of RESONATE BLENDS, INC. stockholders is not obtained, subject to certain limitations; (e) by RESONATE
BLENDS, INC., upon the Asefi Group’s breach of any representation, warranty, covenant or agreement, or if any representation
or warranty of the Asefi Group becomes untrue, in either case such that the conditions set forth in the Purchase Agreement would
not be satisfied as of the time of such breach or as of the time such representation or warranty becomes untrue, subject to cure
provisions; (f) by the Asefi Group, upon RESONATE BLENDS, INC.’ breach of any representation, warranty, covenant or agreement,
or if any representation or warranty of RESONATE BLENDS, INC. becomes untrue, in either case such that the conditions set forth
in the Purchase Agreement would not be satisfied as of the time of such breach or as of the time such representation or warranty
becomes untrue, subject to cure provisions; or (g) by RESONATE BLENDS, INC. if a material adverse effect with respect to the Asefi
Group occurs after the date of execution, subject to cure provisions.
Background
of and Reasons for the Sale of the Resonate Sub’s Shares
On
October 25, 2019, we entered into a Membership Interest Purchase Agreement (the “Resonate Purchase Agreement”) with
Resonate Blends, LLC, a California limited liability company (“Resonate”), and the members of Resonate. As a result
of the transaction, Resonate became a wholly owned subsidiary of the Company. In accordance with the terms of the Purchase Agreement,
at the closing an aggregate of 5% of the Company’s outstanding shares of common stock for a total of 665,072 shares were
issued to the holders of Resonate in exchange for their membership interests of Resonate. These shares have anti-dilution protection.
We have also agreed as part of the purchase price to issue: (ii) such number of shares of Series E Preferred Stock that will convert
into 5% of the outstanding shares of common stock in the Company on a fully-diluted basis upon an annualized revenue run rate
of Ten Million Dollars ($10,000,000.00) for any three (3) consecutive month trailing period; and (iii) such number of shares of
Series E Preferred Stock that will convert into 5% of the outstanding shares of common stock in the Company on a fully-diluted
basis upon the occurrence of the Company’s public market value reaching One Hundred Million US Dollars ($100,000,000). The
shares in (ii) and (iii) shall have anti-dilution protections, except that this provision only applies for 2.5% of the outstanding
shares acquired under each subsection.
The
Resonate Purchase Agreement includes a funding obligation, which requires the Company to provide an aggregate amount of capital
as follows: (i) Five Hundred Thousand Dollars ($500,000) on the Closing Date of, (ii) Five Hundred Thousand ($500,000) four (4)
months after Closing, and (iii) Five Hundred Thousand Dollars ($500,000) eight (8) months after Closing.
At
the time of closing, the Company invested $200,000 and short of what was required at Closing. The Resonate Purchase Agreement
states that the Company will raise an additional $700,000 at terms no less favorable than the funds raised for the $200,000, referred
to above, and provide Resonate the additional $300,000 no later than December 1, 2019, which will be used to pay off the holders
of Series D Preferred Stock prior to its conversion option on December 11, 2019. As previously disclosed, on June 11, 2019, we
entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with the purchasers identified
therein (collectively, the “Purchasers”) providing for the issuance and sale to the Purchasers of an aggregate of
up to 40,000 shares of our Series D Convertible Preferred Stock (the “Preferred Shares”) and related warrants for
gross proceeds to the Company of $200,000. On December 9, 2019, we exercised our right to redeem the Preferred Shares by paying
the Purchasers $260,000 or 130% of the amount paid for the Preferred Shares, as called for under the Securities Purchase Agreement.
Also,
on October 25, 2019, the Company entered into a Membership Interest Purchase Agreement (the “Entourage Labs Purchase Agreement”)
with Entourage Labs, LLC, a California limited liability company (“Entourage Labs”), and the members of Entourage
Labs. As a result of the transaction, Entourage Labs became a wholly owned subsidiary of the Company. In accordance with the terms
of the Purchase Agreement, at the closing an aggregate of 5% of the Company’s outstanding shares of common stock for a total
of 665,072 shares were issued to the holders of Entourage Labs in exchange for their membership interests of Entourage Labs. These
shares have anti-dilution protection. We have also agreed as part of the purchase price to issue: (ii) such number of shares of
Series E Preferred Stock that will convert into 5% of the outstanding shares of common stock in the Company on a fully-diluted
basis upon an annualized revenue run rate of Ten Million Dollars ($10,000,000.00) for any three (3) consecutive month trailing
period; and (iii) such number of shares of Series E Preferred Stock that will convert into 5% of the outstanding shares of common
stock in the Company on a fully-diluted basis upon the occurrence of the Company’s public market value reaching One Hundred
Million US Dollars ($100,000,000). The shares in (ii) and (iii) shall have anti-dilution protections, except that this provision
only applies for 2.5% of the outstanding shares acquired under each subsection.
The
Resonate Purchase Agreement and the Entourage Labs Purchase Agreements are herein referred to herein as the Purchase Agreements.
Resonate
and its Intellectual Property (IP) subsidiary, Entourage Labs, is a California-based cannabis wellness lifestyle product company
built on a proprietary system of experiential targets. Resonate is building a brand-focused and vertically integrated cannabis
organization offering trusted brands of consistent quality. At the heart of the Resonate philosophy is the “Resonate System.”
The System is designed to demystify cannabis and help consumers select effective products by connecting their lifestyle and health
needs with the experience and delivery method that best fits their criteria.
Resonate
plans to launch its first product in a series of infused products in early 2020. The initial launch is expected to be in California
with a statewide distribution system already assembled. Resonate will be executing a multi-state strategy with the goal of becoming
a leading national brand once the California market is optimized. The Company plans to strategically acquire assets and existing
businesses in the cannabis space allowing for a vertically integrated organization centered around the “wellness lifestyle,”
and offer to consumers a family of trusted products that address the fast-growing cannabis market.
The
holding company is assembling the highest quality cultivation, innovation, technology, product development, retail and supply
chain resources to manage and optimize financial performance and assure quality control. Resonate is offering a luxury cannabis-based
wellness lifestyle product family based on consistent quality, unique formulations and maximizing the user experience.
In
addition, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations
(the “Conveyance Agreement”) with Mark S. Johnson and the Company’s 49% owned subsidiary, Aspire Consulting
Group, LLC, a Virginia limited liability company. Pursuant to the Conveyance Agreement, the Company transferred all assets and
business operations associated with its IT consulting solutions, including all of the capital stock of Aspire Consulting, to Mr.
Johnson. In exchange, Mr. Johnson agreed to cancel 20,000 shares of common stock in the Company and to assume and cancel all liabilities
relating to the Company’s former business.
Finally,
the Company entered into Employment Agreements with the following persons: (i) Geoff Selzer as Chief Executive Officer (CEO) of
the Company with an annual salary of $180,000; and (ii) Pam Kerwin as Chief Operating Officer (COO) of the Company with an annual
salary of $120,000. Both are eligible for salary increases upon milestone achievements and other benefits. The Employment Agreement
for the CEO has a term of 2 years and can’t be terminated without cause. Severance of six (6) weeks is available for termination
of the COO without cause before one-year of service and eight (8) weeks after one-year of service.
As
a result of the Purchase Agreements and Conveyance Agreement, the Company intends to carry on the business of Resonate and Entourage
Labs as its primary line of business. The Company has relocated its principal executive offices to 26565 Agoura Road, Suite 200,
Calabasas, CA 91302.
In
line with that decision to make a pure cannabis move, the Purchase Agreements state that if the Resonate Sub does not fit into
that strategy, the board of directors of the Company will divest the Resonate Sub in a method that maximizes shareholder value.
On
February 19, 2020, the board of directors of RESONATE BLENDS, INC. retained TransWorld Business Advisors to commission a Broker
Opinion of Value concerning the proposed Stock Sale.
On
May 22, 2020, the board of directors, after receiving the Broker Opinion of Value, that the terms of the Stock Sale were fair
and reasonable to RESONATE BLENDS, INC. stockholders, approved the sale of the Resonate Sub for 4,822,029 shares of common stock
of RESONATE BLENDS, INC. held by Wais Asefi and the Asefi Group, which will be cancelled and returned to treasury. The 4,822,029
shares have a current market value of $337,542, based on our last sales price of $0.07 per share as of May 26, 2020.
On
May 22, 2020, the board of directors of RESONATE BLENDS, INC. approved the terms of the Stock Sale and authorized the execution
and delivery of the Purchase Agreement with the Asefi Group.
As
of May 22, 2020, RESONATE BLENDS, INC. entered into the Purchase Agreement with the Asefi Group to sell to the Asefi Group the
Resonate Sub. The Purchase Agreement provides that the Stock Sale is subject to customary conditions, including RESONATE BLENDS,
INC.’S receipt of a Broker Opinion of Value from an independent consulting firm and the approval of the Corporation’s
stockholders. Upon consummation of the Stock Sale, RESONATE BLENDS, INC. will no longer have any business operations in the SMS
business but will retain its cannabis operations based in Calabasas, California.
The
board of directors has carefully considered the Stock Sale. The board believes that the price offered by the Asefi Group is the
best reasonably available price for the assets to be sold. In making its decision, our board of directors took into account, among
other things:
|
●
|
the
business outlook of Resonate Sub’s business;
|
|
|
|
|
●
|
the
limited value of the software platform owned by Resonate Sub, given its technological and operational complexity;
|
|
|
|
|
●
|
the
fact that Mr. Asefi contributions in the business of Textmunication, Inc. is vital to the business success of Textmunication,
Inc.
|
|
|
|
|
●
|
RESONATE
BLENDS, INC.’S inability of raising sufficient capital from the public market; the current and future competitive environment
for Resonate Sub’s business;
|
|
|
|
|
●
|
the
determination by the board of directors, after evaluating various strategic alternatives and conducting an extensive review
of our financial condition, results of operations and business prospects, that attempting to raise additional capital, continuing
to operate as a going concern was not reasonably likely to create greater value for our stockholders as compared to the value
obtained for our stockholders pursuant to the Stock Sale;
|
|
●
|
the
board of directors’ belief that as a result of the extent of negotiations with Wais Asefi and the Asefi Group, we obtained
the highest consideration that the Asefi Group was willing to pay or that we were likely to obtain from any other potential
purchase;
|
|
|
|
|
●
|
the
Stock Sale was subject to the approval of our stockholders;
|
|
|
|
|
●
|
the
financial analyses of TransWorld Business Advisors, which we had engaged as our consultant and the opinion of TransWorld Business
Advisors that as of the date of such opinion, and based upon and subject to the various assumptions and qualifications set
forth in its written opinion that the Stock sale was fair to us form a financial point of view, as more fully described below
under the section titled “Pricing Analysis”.
|
In
the course of its deliberations, our board of directors also considered a variety of risks and other countervailing factors, including:
|
●
|
obtaining
approval of the Stock Sale from a majority of the stockholders;
|
|
|
|
|
●
|
the
risks and costs to us if the Stock Sale is not consummated, including the potential liquidation of our company;
|
|
|
|
|
●
|
the
fact that our stockholders will not participate in potential future growth and earnings, if any, of the Resonate Sub; and
|
Pricing
Analysis
The
Purchase Agreement provides that the Stock Sale is subject to RESONATE BLENDS, INC. receiving a final Broker Opinion of Value
through Pricing Analysis from an independent consulting firm that the terms of the Stock Sale were fair to RESONATE BLENDS, INC.
stockholders.
Pursuant
to an engagement letter dated February 19, 2020, we retained TransWorld Business Advisors (“TransWorld.”) to
serve as our consultant in connection with the Stock sale and to render an opinion to the board of directors as to the fairness
from a financial point of view to us of the consideration to be paid by the Asefi Group in the Stock Sale. TransWorld is not a
certified business appraiser and the Broker Opinion of Value is not a certified business appraisal. The information was provided
as a Broker’s Opinion of Value based on available market data.
The
full text of TransWorld’s Broker Opinion of Value is attached as Annex B to this Information Statement and is incorporated
into this Information Statement by reference. The description of TransWorld’s opinion set forth in this Information Statement
is qualified in its entirety by reference to the full text of TransWorld’s opinion. Holders of RESONATE BLENDS, INC. common
stock are encouraged to read TransWorld’s opinion carefully in its entirety for a description of the procedures followed,
assumptions made, matters considered and qualifications and limitations on the scope of work undertaken by TransWorld in connection
with its opinion. TransWorld’s opinion was addressed to the RESONATE BLENDS, INC. board of directors, was only one of many
factors considered by the RESONATE BLENDS, INC. board of directors in their evaluation of the Stock Sale and only addresses the
fairness of the cancellation of Mr. Asefi’s and other’s stock in the Purchase Agreement from a financial point of
view to RESONATE BLENDS, INC. TransWorld’s opinion does not address the relative merits of the Stock Sale as compared to
other business strategies or transactions that might be available to RESONATE BLENDS, INC. or the underlying business decision
of RESONATE BLENDS, INC. to proceed with the Stock Sale and is not intended to, and does not, constitute a recommendation to any
stockholder as to how such stockholder should act with respect to the Stock Sale or related transactions. TransWorld’s opinion
was necessarily based on economic, monetary, market and other conditions as in effect on, and the information made available to
TransWorld as of March 20, 2020, the date of its opinion. TransWorld assumes no responsibility for updating or revising its opinion
based on circumstances or events occurring after the date of the opinion.
RESONATE
BLENDS, INC.’ board of directors selected TransWorld because it has substantial experience in transactions similar to the
Stock Sale. Pursuant to a letter agreement, dated February 19, 2020, RESONATE BLENDS, INC. engaged TransWorld to act as its consultant
solely in connection with the delivery of a pricing analysis with respect to the Stock Sale. Pursuant to the terms of the engagement
letter, RESONATE BLENDS, INC. agreed to pay TransWorld a customary fixed fee for the opinion which is not contingent upon consummation
of the Stock Sale. In addition, RESONATE BLENDS, INC. has agreed to reimburse TransWorld for certain of its expenses.
Company
Determination of Fairness
The
Stock Sale consideration was determined through negotiations between RESONATE BLENDS, INC. and Wais Asefi on behalf of the Asefi
Group and was approved by the RESONATE BLENDS, INC.’S board of directors. TransWorld did not participate in the determination
of the terms of the Stock Sale and did not recommend any specific amount of consideration to RESONATE BLENDS, INC. or RESONATE
BLENDS, INC.’S board of directors or that any specific amount of consideration constituted the only appropriate consideration
for the Stock Sale. TransWorld’s opinion did provide a range of acceptable prices in connection with the Stock Sale, and
RESONATE BLENDS, INC.’S board of directors did consider the opinion in making its determination to proceed with the Stock
Sale. That acceptable range provided by TransWorld was between $252,000 and $374,000 based on the analysis explained. The 4,822,029
shares have a current market value of $337,542, based on our last sales price of $0.07 per share as of May 26, 2020.
As
described above, TransWorld’s opinion to RESONATE BLENDS, INC. was one of many factors taken into consideration by the RESONATE
BLENDS, INC.’S board of directors in making their determination to approve the Purchase Agreement.
We
announced our intention to build a pure play cannabis holding company when we completed the merger with Resonate Blends LLC and
Entourage Labs LLC on October 25, 2019. The Textmunication mobile marketing business does not fit with our overall strategic vision.
Our
designs are to raise capital for the cannabis operations and not the texting business. We need clarity on raising capital for
building value-added cannabis brands – and not supporting our texting operation. We have made it clear through our SEC filings
and Press Releases that our main focus is to become a cannabis product leader through strong leadership, product innovation and
mergers and acquisitions in the cannabis sector. Textmunication, Inc. doesn’t fit in our business model to accomplish such
goals.
Material
Federal Income Tax Consequences
The
following discussion summarizes the material U.S. federal income tax consequences to: (i) RESONATE BLENDS, INC. as a result of
the sale of the shares of Resonate Sub to Wais Asefi pursuant to the Agreement; and (ii) the holders of RESONATE BLENDS, INC.’
Common Stock who are United States holders (as hereafter defined) as a result of such sale. For these purposes, a “United
States holder” is a stockholder that is: (a) a citizen or resident of the United States; (b) a domestic corporation; (c)
an estate whose income is subject to United States federal income tax regardless of its source; or (d) a trust if a United States
court can exercise primary supervision over the trust’s administration and one or more United States persons are authorized
to control all substantial decisions of the trust, or if the trust has a valid election in effect under applicable U.S. Treasury
Regulations to be treated as a United States person. This discussion is based on the Internal Revenue Code of 1986, as amended
(the “Code”), Treasury Regulations promulgated under the Code, Internal Revenue Service rulings, judicial decisions
and administrative rulings as of the date of this Information Statement, all of which are subject to change or differing interpretations,
including changes and interpretations with retroactive effect. No assurance can be given that the tax treatment described in this
Information Statement will remain unchanged at the time of such distributions.
This
discussion is for general information only and may not address all tax considerations that may be significant to a holder of our
common stock. It does not address all U.S. federal income tax consequences or any state, local or foreign tax consequences of
RESONATE BLENDS, INC.’ sale of the shares of Resonate Sub to Wais Asefi. Stockholders subject to special treatment under
certain federal income tax laws, including dealers in securities or foreign currency, tax-exempt entities, non-U.S. stockholders,
banks, thrifts, insurance companies, mutual funds, persons that hold shares of our stock as part of a “straddle,”
a “hedge,” a “constructive sale transaction or a “conversion transaction”, “persons that have”
“functional currency” other than the U.S. dollar, investors in pass-through entities, stockholders subject to the
alternative minimum tax, and persons who acquired their shares of our stock upon exercise of stock options or in other compensatory
transactions may be subject to special rules not discussed below. This discussion also does not address the U.S. federal income
tax consequences to stockholders who do not hold their shares of our stock as a capital asset. Stockholders are urged to consult
their own tax advisors to determine the particular tax consequences.
This
discussion has no binding effect on the Internal Revenue Service or the courts and assumes that the sale of assets will be consummated
in accordance with the Stock Sale Agreement. No ruling has been requested from the Internal Revenue Service, nor will we seek
an opinion of counsel, with respect to the anticipated tax consequences of the sale of assets and the distribution, if any, of
the net cash proceeds to the stockholders. If any of the anticipated tax consequences described herein prove to be incorrect,
the result could be an increased tax liability at the corporate and/or stockholder level, thus reducing the benefits to us and
our stockholders from the sale of assets.
Tax
Consequences to our Stockholders
RESONATE
BLENDS, INC. does not intent to distribute any cash or property to its stockholders in connection with the Agreement between RESONATE
BLENDS, INC. and Wais Asefi. However, if there were any distribution, which are not anticipated, any amounts received by a stockholder
as a result of one or more distributions from RESONATE BLENDS, INC. would be taxed as a dividend to the extent of the stockholder’s
ratable share of RESONATE BLENDS, INC.’ current and accumulated earnings and profits determined on a consolidated basis.
THE
FOREGOING SUMMARY OF U.S. FEDERAL INCOME TAX CONSEQUENCES IS INCLUDED FOR GENERAL INFORMATION ONLY AND DOES NOT CONSTITUTE LEGAL
OR TAX ADVICE TO ANY STOCKHOLDER. EACH STOCKHOLDER IS URGED TO CONSULT A TAX ADVISOR AS TO THE TAX CONSEQUENCES OF THE SALE OF
THE RESONATE SUB SHARES, INCLUDING THE APPLICABILITY AND EFFECT OF ANY STATE, LOCAL OR FOREIGN LAWS AND CHANGES IN APPLICABLE
TAX LAWS.
DISSENTERS’
RIGHT OF APPRAISAL
Under
the NRS, the Corporation’s stockholders are not entitled to dissenters’ rights with respect to the Corporate Actions,
and the Corporation will not independently provide the Corporation’s stockholders with dissenters’ rights.
INTEREST
OF THE CORPORATION AND THE PRESIDENT, SECRETARY AND DIRECTOR IN THE STOCK SALE
None
of our directors or officers or their associates have any interest, direct or indirect, by security holdings or otherwise, in
any of the matters approved by the Majority Stockholders as described in this Information Statement other than Wais Asefi, who
is an affiliate by virtue of his ownership of stock in our company, and is a member of the Asefi Group.
REQUIRED
VOTE
Under
the NRS, the adoption of the Purchase Agreement requires the affirmative vote of holders of a majority of the shares of our voting
stock outstanding on the record date and entitled to vote thereon.
EFFECTS
ON THE CORPORATION IF THE STOCK SALE IS NOT COMPLETED
If
the Stock Sale is not completed, our board of directors, in discharging its fiduciary obligations to our stockholders, will evaluate
other strategic alternatives that may be available, which alternatives may not be as favorable to our stockholders as the Stock
Sale.
RISK
FACTORS RELATED TO THE STOCK SALE
In
addition to the other information contained in this Information statement, you should carefully consider the following risk factors
when deciding whether to vote to approve the Stock Sale Proposal. You should also consider the information in our other reports
on file with the SEC. See “Where You Can Find More Information.”
There
can be no guarantee that the Stock Sale will be completed and, if not completed, it may materially and adversely affect our business,
financial condition and results of operations.
The
consummation of the Stock Sale is subject to certain closing conditions. No assurance can be given whether such conditions will
be obtained. If the Stock Sale is not consummated, we may be subject to a number of risks, including the following:
|
●
|
we
may not be able to identify an alternate transaction, or if an alternate transaction is identified, such alternate transaction
may not result in an equivalent price to what is proposed in the Stock Sale;
|
|
|
|
|
●
|
the
trading price of our common stock may decline to the extent that the then current market price reflects a market assumption
that the Stock Sale will be consummated; and
|
|
|
|
|
●
|
our
relationships with our customers, suppliers and employees may be damaged beyond repair and the value of our assets will likely
significantly decline.
|
The
occurrence of any of these events individually or in combination will likely materially and adversely affect our business, financial
condition and results of operations, cause the market value of our common stock to significantly decline or become worthless and
force us to file for bankruptcy protection, liquidate and/or windup our operations. If we were to liquidate, it is unlikely that
common stockholders or junior preferred stockholders will receive any liquidation distributions.
Even
if the Stock Sale is consummated, we cannot assure you that the remaining U.S. business or any new business that we may acquire
will be successful.
We
intend to engage in the cannabis industry in the United States as well as to seek new business opportunities in new lines of business
if the Stock Sale is consummated. There is a risk that we will be unsuccessful in expanding the current U.S. operations and that
we will be unable to find a suitable acquisition candidate or successfully operate any new line of business or be able to successfully
integrate it with our current management and structure. Our estimates of capital, personnel and equipment required to expand our
current business or for our new line of business are based on the experience of management and businesses they are familiar with.
We are subject to the risks such as our ability to implement our business plan, market acceptance of our proposed business and
services, under-capitalization, cash shortages, limitations with respect to personnel, financing and other resources, competition
from better funded and experienced companies, and uncertainty of our ability to generate revenues. There is no assurance that
our activities will be successful or will result in any revenues or profit, and the likelihood of our success must be considered
in light of the stage of our development. Even if we generate additional revenue, there can be no assurance that we will be profitable.
We have insufficient results for investors to use to identify historical trends or even to make quarter to quarter comparisons
of our operating results. You should consider our prospects in light of the risk, expenses and difficulties we will encounter
as an early stage company. Our revenue and income potential is unproven and our business model is continually evolving. We are
subject to the risks inherent to the operation of a new business enterprise, and cannot assure you that we will be able to successfully
address these risks.
Our
future plans and operations may require that we raise additional capital.
As
of December 31, 2019, we had cash of $53,139. We do not know that the remaining cash will be sufficient to allow us to implement
our anticipated plan of operations or meet our future anticipated cash flow requirements. If we require additional capital, it
may not be available on terms that are favorable to us, if at all.
The
tax treatment of the Stock Sale or any liquidating distributions may vary from stockholder to stockholder, and the discussions
in this Information Statement regarding such tax treatment are general in nature.
You
should consult your own tax advisor instead of relying on the discussions of tax treatment in this Information Statement for tax
advice.
We
have not requested a ruling from the IRS with respect to the anticipated tax consequences of the Stock Sale, and we will not seek
an opinion of counsel with respect to the anticipated tax consequences of the Stock Sale. If any of the anticipated tax consequences
described in this Information Statement proves to be incorrect, the result could be increased taxation at the corporate and/or
stockholder level, thus reducing the benefit to our stockholders and us from the liquidation and distributions. Tax considerations
applicable to particular stockholders may vary with and be contingent upon the stockholder’s individual circumstances.
We
may be subject to securities litigation, which is expensive and could divert our attention.
We
may be subject to securities class action litigation in connection with the Stock Sale. Securities litigation against us could
result in substantial costs and divert our management’s attention from closing the Stock Sale, which could harm our business
and increase our expenses.
UNAUDITED
PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET
The
following unaudited pro forma condensed consolidated financial statements are based upon our historical consolidated statements,
adjusted to give effect to the sale of our subsidiary Textmunication, Inc., which constitutes substantially all of the assets
of the Corporation in accordance with the Stock Purchase Agreement between the Corporation and Textmunication, Inc. These unaudited
pro forma condensed consolidated financial statements are derived from, and should be read in conjunction with, the Corporation’s
Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on May 13, 2020.
The
unaudited pro forma condensed consolidated balance sheet gives effect to the proposed sale of our subsidiary, Textmunication,
Inc., which constitutes substantially all of the assets of the Corporation, as if it had occurred on December 31, 2019. The proceeds,
in the form of a cancellation of Corporation shares and impact of the resulting gain are only included in the December 31, 2019
unaudited pro forma condensed consolidated balance sheet. The unaudited pro forma condensed consolidated statements of operations
for the year ended December 31, 2019 give effect to the sale of Textmunication, Inc.as if it had occurred on December 31, 2019.
The
pro forma adjustments related to the sale of our subsidiary Textmunication, Inc., which constitutes substantially all of the assets
of the Corporation, is based on available information and assumptions that management believes are (1) directly attributable to
the sale of Textmunication, Inc..; (2) factually supportable; and (3) with respect to the unaudited pro forma condensed consolidated
statements of operations, expected to have a continuing impact on consolidated operating results. Certain of the most significant
assumptions are set forth under the Notes to Unaudited Pro Forma Condensed Consolidated Financial Statements.
We
have included the following unaudited pro forma condensed consolidated financial information solely for the purpose of providing
stockholders with information that may be useful for purposes of considering and evaluating the proposal to approve the sale of
our subsidiary Textmunication, Inc., which constitutes substantially all of the assets of the Corporation. The unaudited pro forma
condensed consolidated financial information is not necessarily indicative of the results of operations or financial position
that might have been achieved for the dates or periods indicated, nor is it indicative of the results of operations or financial
position that may occur in the future.
The
unaudited pro forma consolidated financial information is provided for illustrative purposes only and does not purport to represent
what the actual results of operations would have been had the sale of our subsidiary Textmunication, Inc., which constitutes substantially
all of the assets of the Corporation, occurred on the respective dates assumed, nor is it necessarily indicative of our future
operating results. The unaudited pro forma condensed consolidated financial information does not purport to reflect what we anticipate
the actual state of operations to be following the completion of the sale of our subsidiary Textmunication, Inc., which constitutes
substantially all of the assets of the Corporation. Furthermore, in future reports that we file with the SEC, the pro forma
adjustments may differ from those that will be calculated for purposes of reporting discontinued operations in future filings.
We caution stockholders that our future results of operations, including uses of cash and financial position, will significantly
differ from those described in these unaudited pro forma condensed consolidated financial statements, and accordingly, these unaudited
pro forma condensed consolidated financial statements should be read in conjunction with the disclosures in the information statement
to which they are attached regarding the nature of our business following completion of the transaction The unaudited pro forma
consolidated financial information and the accompanying unaudited notes should be read in conjunction with our consolidated financial
statements and notes thereto included by reference in this information statement.
TEXTMUNICATION
HOLDINGS, INC.
PRO
FORMA CONSOLIDATED BALANCE SHEETS
As
of December 31, 2019
|
|
|
|
|
Textmunication
|
|
|
Resonate
|
|
|
|
Consolidated
|
|
|
Inc
|
|
|
Holdings
Inc.
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
Current
assets
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
and cash equivalents
|
|
$
|
53,139
|
|
|
$
|
50,024
|
|
|
|
3,115
|
|
Receivables
|
|
|
52,603
|
|
|
|
52,603
|
|
|
|
-
|
|
Total
current assets
|
|
|
105,742
|
|
|
|
102,627
|
|
|
|
3,115
|
|
Investment
in equity method investee
|
|
|
25,000
|
|
|
|
-
|
|
|
|
25,000
|
|
TOTAL
ASSETS
|
|
|
130,742
|
|
|
|
102,627
|
|
|
|
28,115
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES
AND STOCKHOLDERS’ DEFICIT
|
|
|
|
|
|
|
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
|
-
|
|
|
|
-
|
|
Accounts
payable and accrued liabilities
|
|
|
175,243
|
|
|
|
115,913
|
|
|
|
59,330
|
|
Due
to related parties
|
|
|
11,650
|
|
|
|
11,750
|
|
|
|
(100
|
)
|
Convertible
notes payable, net of discount
|
|
|
171,436
|
|
|
|
-
|
|
|
|
171,436
|
|
Derivative
liability
|
|
|
89,145
|
|
|
|
-
|
|
|
|
89,145
|
|
Settlement
liability
|
|
|
106,961
|
|
|
|
-
|
|
|
|
106,961
|
|
Total
current liabilities
|
|
|
554,435
|
|
|
|
127,663
|
|
|
|
426,772
|
|
Convertible
notes payable, net of discount - Long term
|
|
|
|
|
|
|
-
|
|
|
|
|
|
Total
liabilities
|
|
|
554,435
|
|
|
|
127,663
|
|
|
|
426,772
|
|
Stockholders’
deficit
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred
stock, 5,933,333 shares authorized, $0.0001 par value, 4,000,000 issued and outstanding
|
|
|
400
|
|
|
|
-
|
|
|
|
400
|
|
Series
B - Preferred stock, 66,667 shares authorized, $0.0001 par value, 66,667 issued and outstanding
|
|
|
0
|
|
|
|
-
|
|
|
|
-
|
|
Series
C - Preferred stock, 2,000,000 shares authorized, $0.0001 par value, 2,000,000 issued and outstanding
|
|
|
200
|
|
|
|
-
|
|
|
|
200
|
|
Common
stock; $0.0001 par value; 100,000,000 shares authorized; 17,153,936 and 2,435,179 shares issued and outstanding as of December
31, 2019 and 2018, respectively.
|
|
|
1,715
|
|
|
|
-
|
|
|
|
1,715
|
|
Additional
paid-in capital
|
|
|
18,475,986
|
|
|
|
-
|
|
|
|
18,475,986
|
|
Accumulated
deficit
|
|
|
(18,901,994
|
)
|
|
|
(25,036
|
)
|
|
|
(18,876,958
|
)
|
Total
Stockholders’ deficit
|
|
|
(423,693
|
)
|
|
|
(25,036
|
)
|
|
|
(398,657
|
)
|
TOTAL
LIABILITIES AND STOCKHOLDER’S EQUITY
|
|
$
|
130,742
|
|
|
$
|
102,627
|
|
|
$
|
28,115
|
|
The
accompanying notes are an integral part of these unaudited consolidated financial statements
TEXTMUNICATION
HOLDINGS, INC.
PRO
FORMA CONSOLIDATED STATEMENTS OF OPERATIONS
FOR
THE YEARE ENDED
DECEMBER
31, 2019
|
|
|
|
|
Textmunication
|
|
|
Resonate
|
|
|
|
Consoidated
|
|
|
Inc
|
|
|
Holding
Inc.
|
|
REVENUES
|
|
$
|
1,050,161
|
|
|
$
|
1,050,161
|
|
|
$
|
-
|
|
COST
OF REVENUES
|
|
|
392,674
|
|
|
|
392,674
|
|
|
|
-
|
|
Gross
profit
|
|
|
657,487
|
|
|
|
657,487
|
|
|
|
-
|
|
Operating
expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
Advertising
|
|
|
60,776
|
|
|
|
21,831
|
|
|
|
38,944
|
|
General
and administrative expenses
|
|
|
154,905
|
|
|
|
115,854
|
|
|
|
39,052
|
|
Legal
and Professional fees
|
|
|
247,846
|
|
|
|
49,828
|
|
|
|
198,018
|
|
Officer
Compensation
|
|
|
475,910
|
|
|
|
300,910
|
|
|
|
175,000
|
|
Salaries
and Related
|
|
|
287,034
|
|
|
|
213,534
|
|
|
|
73,500
|
|
Sales
Commission
|
|
|
82,236
|
|
|
|
82,236
|
|
|
|
-
|
|
Office
Rent
|
|
|
22,050
|
|
|
|
22,050
|
|
|
|
-
|
|
Impairment
of inhouse software
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Non
cash management fees
|
|
|
2,556,326
|
|
|
|
-
|
|
|
|
2,556,326
|
|
Total
operating expenses
|
|
|
3,887,083
|
|
|
|
806,243
|
|
|
|
3,080,840
|
|
Loss
from operations
|
|
|
(3,229,596
|
)
|
|
|
(148,756
|
)
|
|
|
(3,080,840
|
)
|
Other
Income (expense)
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
Income
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
expense
|
|
|
(91,426
|
)
|
|
|
(10,870
|
)
|
|
|
(80,556
|
)
|
Loss
on change of derivative liability
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Amortization
of debt discount
|
|
|
(42,359
|
)
|
|
|
-
|
|
|
|
(42,359
|
)
|
Gain
on settlement of derivative liabilities
|
|
|
44,528
|
|
|
|
-
|
|
|
|
44,528
|
|
Legal
settlement
|
|
|
(106,961
|
)
|
|
|
-
|
|
|
|
(106,961
|
)
|
Gain
on settlement of notes payable
|
|
|
24,939
|
|
|
|
-
|
|
|
|
24,939
|
|
Total
other expense
|
|
|
(171,279
|
)
|
|
|
(10,870
|
)
|
|
|
(160,409
|
)
|
Income
(loss) from investment in equity method investee
|
|
|
(11,125
|
)
|
|
|
-
|
|
|
|
(11,125
|
)
|
NET
INCOME (LOSS)
|
|
$
|
(3,412,000
|
)
|
|
$
|
(159,626
|
)
|
|
$
|
(3,252,374
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
weighted average common shares outstanding
|
|
|
11,242,260
|
|
|
|
|
|
|
|
|
|
Net
Income (loss) per common share: basic and diluted
|
|
|
(0.30
|
)
|
|
|
|
|
|
|
|
|
The
accompanying notes are an integral part of these unaudited consolidated financial statements
AMENDMENT
TO OUR ARTICLES OF INCORPORATION
INCREASE
IN AUTHORIZED COMMON STOCK
Purpose
of and Rationale for the Amendment
We
are currently authorized to issue a total of one hundred million (100,000,000) shares of Common Stock. Of this amount, 23,950,843
shares of Common Stock were outstanding as of May 22, 2020.
We
are required to reserve sufficient shares of Common Stock for issuance upon conversion or exercise of our outstanding convertible
debt securities and our Employee Stock Ownership Program (“ESOP”). We have reserved
with our transfer agent approximately 49,266,000 shares of Common Stock for these conversions. We have 3,515,000 shares reserved
under our ESOP.
Our
Board of Directors has determined that it is in our best interest to increase the number of authorized shares of Common Stock
to cover the aforementioned conversions and shares reserved for our ESOP. In addition, the Board of Directors believes that the
Amendment will provide us with greater flexibility by increasing our authorized capital to allow us to issue additional shares
of Common Stock as the Board of Directors deems necessary or advisable.
As
a result, our current authorized shares of 100,000,000 is insufficient to cover the estimated 49,266,000 shares of Common Stock
necessary for issuance upon exercise or conversion of our convertible debt, the increases to the existing reservations to cover
the anticipated decrease in our stock price as a result of the conversions, to reserve our ESOP and to plan for future financings.
Consequently, the Amendment to increase our authorized shares of Common Stock is
necessary in order to validly issue shares of common stock upon the conversion or exercise of these securities, to fund our ESOP
and to provide for future financings.
A
copy of the Amendment is included as Annex C to this Information Statement.
The
Board of Directors believes that an increase in the total number of shares of authorized Common Stock will give us greater flexibility
in responding quickly to advantageous financing and business opportunities that involve the direct or indirect issuance of additional
shares of common stock and attracting and retaining key personnel through the issuance of stock incentive awards. The Amendment
to increase our authorized Common Stock will not have any immediate effect on the rights of existing stockholders. However, our
Board of Directors will have the authority to issue authorized common stock or other securities convertible into or exercisable
or exchangeable for common stock without requiring future stockholder approval of such issuances, except as may be required by
our Articles of Incorporation or applicable law. To the extent that additional authorized shares are issued in the future, they
may decrease the existing stockholders’ percentage equity ownership and, depending on the price at which they are issued,
could be dilutive to the existing stockholders. The increase in the authorized number of shares of Common Stock and the subsequent
issuance of such shares could have the effect of delaying or preventing a change in control of our company without further action
by our stockholders. Shares of authorized and unissued Common Stock could, within the limits imposed by applicable law, be issued
in one or more transactions which would make a change in control of our company more difficult, and therefore less likely. Any
such issuance of additional stock could have the effect of diluting the earnings per share and book value per share of outstanding
shares of Common Stock and such additional shares could be used to dilute the stock ownership or voting rights of a person seeking
to obtain control of our company. The Board of Directors is not currently aware of any attempt to take over or acquire our company.
While it may be deemed to have potential anti-takeover effects, the amendment is not prompted by any specific effort or takeover
threat currently perceived by management.
One
of the effects of the increase in authorized share capital, if adopted, however, may be to enable the Board to render it more
difficult to or discourage an attempt to obtain control of the Company by means of a merger, tender offer, proxy contest or otherwise,
and thereby protect the continuity of present management. The Board would, unless prohibited by applicable law, have additional
shares of Common Stock available to effect transactions (including private placements) in which the number of the Company’s
outstanding shares would be increased and would thereby dilute the interest of any party attempting to gain control of the Company.
Such action, however, could discourage an acquisition of the Company, which the stockholders of the Company might view as desirable.
Effect
on Outstanding Common Stock
The
additional shares of Common Stock authorized by the Amendment will have the same privileges as the shares of Common Stock currently
authorized and issued. Stockholders do not have preemptive rights under our Articles of Incorporation and will not have such rights
with respect to the additional authorized shares of Common Stock. The increase in authorized shares would not affect the terms
or rights of holders of existing shares of Common Stock. All outstanding shares of Common Stock will continue to have one vote
per share on all matters to be voted on by our stockholders, including the election of directors.
The
issuance of any additional shares of Common Stock may, depending on the circumstances under which those shares are issued, reduce
stockholders’ equity per share and, unless additional shares are issued to all stockholders on a pro rata basis, will reduce
the percentage ownership of Common Stock of existing stockholders. In addition, if our Board of Directors elects to issue additional
shares of Common Stock, such issuance could have a dilutive effect on the earnings per share, voting power and shareholdings of
current stockholders. We expect, however, to receive consideration for any additional shares of Common Stock issued, thereby reducing
or eliminating any adverse economic effect to each stockholder of such dilution.
The
Amendment will not otherwise alter or modify the rights, preferences, privileges or restrictions of the Common Stock.
Interests
of Certain Persons in the Action
Aside
from the noteholders that may convert their debt into Common Stock, we do not believe that there are stockholders with interests
in the Amendment that are different from or greater than those of any other of our stockholders.
Anti-Takeover
Effects
Although
the Amendment is not motivated by anti-takeover concerns and is not considered by our Board of Directors to be an anti-takeover
measure, the availability of additional authorized shares of Common Stock could enable the Board of Directors to issue shares
defensively in response to a takeover attempt or to make an attempt to gain control of the Company more difficult or time-consuming.
For example, shares of Common Stock could be issued to purchasers who might side with management in opposing a takeover bid that
the Board of Directors determines is not in our best interests, thus diluting the ownership and voting rights of the person seeking
to obtain control of the Company. In certain circumstances, the issuance of Common Stock without further action by the stockholders
may have the effect of delaying or preventing a change in control of the Company, may discourage bids for our Common Stock at
a premium over the prevailing market price and may adversely affect the market price of our Common Stock. As a result, increasing
the authorized number of shares of our Common Stock could render more difficult and less likely a hostile takeover, tender offer
or proxy contest, assumption of control by a holder of a large block of our stock, and the possible removal of our incumbent management.
We are not aware of any proposed attempt to take over the Company or of any present attempt to acquire a large block of our Common
Stock.
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
AND RELATED STOCKHOLDER MATTERS
The
following table sets forth, as of May 22, 2020, certain information as to shares of our common stock owned by (i) each person
known by us to beneficially own more than 5% of our outstanding common stock, (ii) each of our directors, and (iii) all of our
executive officers and directors as a group. Unless otherwise stated, the address for each beneficial owner is at 26565 Agoura
Road, Suite 200 Calabasas, CA 91302.
Name
and Address of Beneficial Owner
|
|
Common
Stock
|
|
|
Series
C
Preferred Stock
|
|
|
|
Number
of Shares
Owned
|
|
|
Percent
of
Class(1)(2)
|
|
|
Number
of Shares
Owned
|
|
|
Percent
of
Class(1)(2)
|
|
Geoffrey
Selzer
|
|
|
1,053,312
|
|
|
|
4.4
|
%
|
|
|
2,000,000
|
|
|
|
100
|
%
|
David
Thielen
|
|
|
1,500,000
|
|
|
|
6.3
|
%
|
|
|
-
|
|
|
|
-
|
|
Pam
Kerwin
|
|
|
124,228
|
|
|
|
0.5
|
%
|
|
|
-
|
|
|
|
-
|
|
All
Directors and Executive Officers as a Group (3 persons)
|
|
|
2,677,540
|
|
|
|
11.7
|
%
|
|
|
2,000,000
|
|
|
|
100
|
%
|
5% Holders
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Wais
Asefi
|
|
|
2,722,029
|
|
|
|
11.3
|
%
|
|
|
-
|
|
|
|
-
|
|
Nick
Miniello
|
|
|
1,500,000
|
|
|
|
6.3
|
%
|
|
|
-
|
|
|
|
-
|
|
|
(1)
|
Pursuant
to Rules 13d-3 and 13d-5 of the Exchange Act, beneficial ownership includes any shares as to which a shareholder has sole
or shared voting power or investment power, and also any shares which the shareholder has the right to acquire within 60 days,
including upon exercise of common shares purchase options or warrants.
|
|
(2)
|
The
percent of class is based on 23,950,843 shares of common stock outstanding and 2,000,000 shares of Series C Preferred Stock
outstanding as of May 22, 2020.
|
NOTICE
REGARDING DELIVERY OF STOCKHOLDER DOCUMENTS
(“HOUSEHOLDING” INFORMATION)
The
SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for information
statements by delivering a single copy of these materials to an address shared by two or more stockholders. This process, which
is commonly referred to as “householding,” potentially means extra convenience for stockholders and cost savings for
companies and intermediaries. A number of brokers and other intermediaries with account holders who are our stockholders may be
householding our stockholder materials, including this Information Statement. In that event, a single Information Statement, as
the case may be, will be delivered to multiple stockholders sharing an address unless contrary instructions have been received
from the affected stockholders. Once you have received notice from your broker or other intermediary that it will be householding
communications to your address, householding will continue until you are notified otherwise or until you revoke your consent,
which is deemed to be given unless you inform the broker or other intermediary otherwise when you receive or received the original
notice of householding. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate
Information Statement, please notify your broker or other intermediary to discontinue householding and direct your written request
to receive a separate Information Statement to us at:
RESONATE
BLENDS, INC.
26565
Agoura Road, Suite 200
Calabasas,
CA 91302
571-888-0009
Stockholders
who currently receive multiple copies of the proxy statement at their address and would like to request householding of their
communications should contact their broker or other intermediary.
Annex
A
STOCK
PURCHASE AGREEMENT
STOCK
PURCHASE AGREEMENT (the “Agreement”) made as of this 22nd day of May, 2020, by and between Resonate Blends,
Inc., a Nevada corporation (the “Seller”), and Wais Asefi (“Asefi”), Nick Miniello, Juleon
Asefi, and Curt Byers (each a “Buyer”, and collectively, the “Buyers”).
WITNESSETH:
WHEREAS,
the Seller owns one hundred percent (100%) of the outstanding common stock (the “Shares”), of Textmunication,
Inc., a California corporation (the “Company”), and the Buyers desire to purchase from the Seller, and Seller
desires to sell, the Shares upon the terms and conditions hereinafter set forth herein.
WHEREAS,
simultaneously with the execution and delivery hereof and subject to the consummation of the transactions contemplated hereby,
the Seller and Asefi are entering into the Separation Agreement and Release (the “Termination Agreement”),
in the form attached hereto as Exhibit A.
NOW,
THEREFORE, in consideration of the mutual covenants and promises herein contained and upon the terms and conditions hereinafter
set forth, the parties hereto, intending to be legally bound, agree as follows:
ARTICLE
I
PURCHASE
AND SALE OF SHARES.
Upon
the terms and conditions herein contained, at the Closing (as hereinafter defined), the Seller will sell, assign and transfer
to the Buyers and the Buyers will purchase from the Seller all rights of the Seller in and to the Shares (the “Sale”),
free and clear of all liens, claims, pledges, mortgages, restrictions, obligations, security interests and encumbrances of any
kind, nature and description. The Shares shall be allocated among the Buyers as set forth in Annex
A hereto.
ARTICLE
II
CONSIDERATION
In
consideration for the Shares, the Buyer shall deliver to the Seller for cancellation 4,822,029 shares of common stock, par value
$0.0001 per share, of Seller (the “KOAN Shares”).
ARTICLE
III
CLOSING
The
closing of the transactions contemplated by this Agreement (the “Closing”) shall take place at the offices
of the Company, at 10:00 a.m. (local time) on the date that is two business days following the satisfaction or waiver of each
of the conditions set forth in Article 8 unless Buyers and Seller agree otherwise.
ARTICLE
IV
SELLER
REPRESENTATIONS AND WARRANTIES.
Seller
hereby represents and warrants to Buyers, as of the date hereof and as of the Closing Date as though made at the Closing Date,
subject to such exceptions as are specifically disclosed in writing (with reference to a specific section of this Agreement to
which each such exception applies; provided, however, that if any section of the Seller Disclosure
Letter, as defined below, discloses an item or information in such a way as to make its relevance to the disclosure required by
another section reasonably apparent based upon the substance of such disclosure, the matter shall be deemed to have been disclosed
in such other section of the Seller Disclosure Letter, notwithstanding the omission of an appropriate cross-reference to such
other section) in a disclosure letter supplied by Seller to the Buyers, dated as of the date hereof and certified by a duly authorized
officer of Seller (the “Seller Disclosure Letter”), as follows:
4.1
Organization and Qualification.
(a)
Each of Seller, the Company and the Company’s subsidiaries is a corporation duly organized, validly existing and in good
standing under the laws of the respective jurisdiction of its incorporation and has the requisite corporate power and authority
to own, lease and operate its assets and properties and to carry on its business as it is now being conducted. Each of the Company
and its subsidiaries is in possession of all franchises, grants, authorizations, licenses, permits, easements, consents, certificates,
approvals and orders (“Approvals”) necessary to own, lease and operate the properties it purports to own, operate
or lease and to carry on its business as it is now being conducted, except where the failure to have such Approvals would not,
individually or in the aggregate, have a Material Adverse Effect (as defined in Section 11.3(c)) on the Company or its subsidiaries.
Each of the Company and its subsidiaries is duly qualified or licensed as a foreign corporation to do business, and is in good
standing, in each jurisdiction where the character of the properties owned, leased or operated by it or the nature of its activities
makes such qualification or licensing necessary, except for such failures to be so duly qualified or licensed and in good standing
that would not, either individually or in the aggregate, have a Material Adverse Effect on the Company or its subsidiaries.
(b)
The Company has no subsidiaries except for the entities identified in Section 4.1(b) of the Seller Disclosure Letter. Neither
the Company nor any of its subsidiaries has agreed, is obligated to make, or is bound by, any written, oral or other agreement,
contract, sub-contract, lease, binding understanding, instrument, note, option, warranty, purchase order, license, sub-license,
insurance policy, benefit plan, commitment, or undertaking of any nature, as of the date hereof or as may hereafter be in effect
under which it may become obligated to make, any future investment in or capital contribution to any other entity. Neither the
Company nor any of its subsidiaries directly or indirectly owns any equity or similar interest in or any interest convertible,
exchangeable or exercisable for, any equity or similar interest in, any corporation, partnership, joint venture or other business,
association or entity.
4.2
Certificate of Incorporation and Bylaws. The Company and each of its subsidiaries has previously furnished to the Buyers
a complete and correct copy of its Certificate of Incorporation and Bylaws or any equivalent organizational documents, as amended
to date. Such Certificate of Incorporation, Bylaws and equivalent organizational documents of the Company and each of its subsidiaries
are in full force and effect. Neither the Company nor any of its subsidiaries is in violation of any of the provisions of its
Certificate of Incorporation or Bylaws or equivalent organizational documents.
4.3
Capitalization.
(a)
The authorized capital stock of the Company consists of ten million (10,000,000) shares of common stock, no par value, of which
only the Shares are issued and outstanding. The Shares have been duly authorized and are validly issued, fully paid and non-assessable.
Except as set forth in Section 4.3 (a) of the Seller Disclosure Letter, the Company owns all of the issued and outstanding shares
of its subsidiaries, which shares have been duly authorized and are validly issued, fully paid and non-assessable. The Shares
and all outstanding shares of capital stock of each subsidiary of the Company have been issued and granted in compliance with
(i) all applicable securities laws and other applicable federal, state, local, municipal, foreign or other law, statute, constitution,
principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issues, enacted,
adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Entity (as defined
below) and (ii) all requirements set forth in applicable contracts, agreements, and instruments.
(b)
Seller owns the Shares free and clear of all liens, pledges, hypothecations, charges, mortgages, security interests, encumbrances,
claims, infringements, interferences, options, right of first refusals, preemptive rights, community property interests or restriction
of any nature (including any restriction on the voting of any security, any restriction on the transfer of any security or other
asset, any restriction on the possession, exercise or transfer of any other attribute of ownership of any asset) directly or indirectly
through one or more subsidiaries, as of the date of this Agreement, there are no equity securities, partnership interests or similar
ownership interests of any class of equity security of the Company or any subsidiary of the Company, or any security exchangeable
or convertible into or exercisable for such equity securities, partnership interests or similar ownership interests, issued, reserved
for issuance or outstanding. There are no subscriptions, options, warrants, equity securities, partnership interests or similar
ownership interests, calls, rights (including preemptive rights), commitments or agreements of any character to which Seller,
the Company or any of their subsidiaries is a party or by which they are bound obligating Seller, the Company or any of their
subsidiaries to issue, deliver or sell, or cause to be issued, delivered or sold, or repurchase, redeem or otherwise acquire,
or cause the repurchase, redemption or acquisition of, any shares of capital stock, partnership interests or similar ownership
interests of the Company or any of its subsidiaries or obligating the Company or any of its subsidiaries to grant, extend, accelerate
the vesting of or enter into any such subscription, option, warrant, equity security, call, right, commitment or agreement. As
of the date of this Agreement, there are no registration rights and there is, no voting trust, stockholders’ agreement,
proxy, rights plan, antitakeover plan or other agreement or understanding to which the Company or any of its subsidiaries is a
party or by which they are bound with respect to any equity security of any class of Company or with respect to any equity security,
partnership interest or similar ownership interest of any class of any of its subsidiaries.
4.4
Authority. Seller has all necessary corporate power and authority to execute and deliver this Agreement and the Termination
Agreement and to perform its respective obligations hereunder and thereunder and, subject to obtaining the approval of the stockholders
of Seller of the Sale, to consummate the transactions contemplated hereby and thereby. The execution and delivery of each of this
Agreement and the Termination Agreement by Seller and the consummation by Seller of the transactions contemplated hereby and thereby
have been duly and validly authorized by all necessary corporate action on the part of Seller and no other corporate proceedings
on the part of Seller are necessary to authorize this Agreement or the Termination Agreement or to consummate the transactions
so contemplated (other than, with respect to the Sale, the approval and adoption of this Agreement and the approval of the Sale
by holders of a majority of the outstanding shares of Seller’s capital stock in accordance with Nevada Law and Seller’s
Articles of Incorporation and Bylaws). Each of this Agreement and the Termination Agreement has been duly and validly executed
and delivered by Seller and, assuming the due authorization, execution and delivery by other party or partis thereto, constitutes
legal and binding obligations of Seller, enforceable against Seller in accordance with their respective terms.
4.5
No Conflict; Required Filings and Consents.
(a)
The execution and delivery of this Agreement and the Termination Agreement by Seller does not, and the performance of this Agreement
by Seller will not, (i) conflict with or violate the Articles of Incorporation or Bylaws or equivalent organizational documents
of Seller or any of its subsidiaries, (ii) subject to obtaining the approval of Seller’s stockholders in favor of approval
and adoption of this Agreement and approval of the Sale, and obtaining the consents, approvals, authorizations and permits and
making registrations, filings and notifications set forth in Section 4.5(b) hereof (or Section 4.5(b) of the Seller
Disclosure Letter), to the best of Seller’s knowledge, conflict with or violate any law, rule, regulation, order, judgment
or decree applicable to Seller, the Company or any of their respective subsidiaries or by which any of their respective properties
is bound or affected, or (iii) result in any breach of or constitute a default (or an event that with notice or lapse of time
or both would become a default) under, or impair the Company’s or any of its subsidiaries rights or alter the rights or
obligations of any third party under, or give to others any rights of termination, amendment, acceleration or cancellation of,
or result in the creation of a lien or encumbrance on any of the properties or assets of the Company or any of its subsidiaries
pursuant to, any material note, bond, mortgage, indenture, contract, agreement, lease, license, permit, franchise or other instrument
or obligation to which Seller, the Company or any of their subsidiaries is a party or by which Seller, the Company, any of their
subsidiaries or any of their respective properties are bound or affected, except in the case of clauses (ii) and (iii), to the
extent such conflict, violation, breach, default, impairment or other effect could not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect on the Company or its subsidiaries.
(b)
The execution and delivery of each of this Agreement and the Termination Agreement by Seller does not, and the performance of
each of this Agreement and the Termination Agreement by Seller will not, require any consent, approval, authorization or permit
of, or registration, filing with or notification to, any court, administrative agency, commission, governmental or regulatory
authority, domestic or foreign (each, a “Governmental Entity” and, collectively, “Governmental Entities”),
except for, in the case of this Agreement, (i) applicable requirements, if any, of the Securities Act of 1933, as amended (the
“Securities Act”), the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
state securities laws (“Blue Sky Laws”), and the rules and regulations promulgated thereunder and (ii) where
the failure to obtain such consents, approvals, authorizations or permits, or to make such filings or notifications, (A) would
not prevent consummation of the Sale or otherwise prevent Seller from performing its obligations under this Agreement or the Termination
Agreement, or (B) could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on the
Company or its subsidiaries.
4.6
SEC Filings. Seller has made available to the Buyers a correct and complete copy of each report, schedule, registration
statement and definitive proxy statement filed by Seller with the Securities and Exchange Commission (the “SEC”)
on or after January 1, 2018 and prior to the date of this Agreement (the “Seller SEC Reports”), which are all
the forms, reports and documents required to be filed by Seller with the SEC since such date. The Seller SEC Reports (i) were
prepared in accordance with the requirements of the Securities Act or the Exchange Act, as the case may be, and (ii) did not at
the time they were filed (or if amended or superseded by a filing prior to the date of this Agreement then on the date of such
filing) contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
in order to make the statements therein, in light of the circumstances under which they were made, not misleading. Neither the
Company nor any of its subsidiaries is required to file any reports or other documents with the SEC.
4.7
Compliance; Permits.
(a)
Neither the Company nor any of its subsidiaries is in conflict with, or in default or violation of, (i) any law, rule, regulation,
order, judgment or decree applicable to the Company or any of its subsidiaries or by which its or any of their properties is bound
or affected, or (ii) any material note, bond, mortgage, indenture, contract, agreement, lease, license, permit, franchise or other
instrument or obligation to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries
or its or any of their respective properties is bound or affected, except for any conflicts, defaults or violations that (individually
or in the aggregate) would not have a Material Adverse Effect on the Company or its subsidiaries. No investigation or review by
any governmental or regulatory body or authority is pending or, to the knowledge of Seller, threatened against the Company or
its subsidiaries, nor has any governmental or regulatory body or authority indicated an intention to conduct the same, other than,
in each such case, those the outcome of which could not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect on the Company or its subsidiaries.
(b)
The Company and its subsidiaries hold all permits, licenses, variances, exemptions, orders and approvals from Governmental Entities
which are material to the operation of the business of the Company and its subsidiaries (collectively, the “Company Permits”).
The Company and its subsidiaries are in compliance in all material respects with the terms of the Company Permits.
4.8
No Undisclosed Liabilities; Controls.
(a)
Neither the Company nor any of its subsidiaries has any liabilities (absolute, accrued, contingent or otherwise) of a nature required
to be disclosed on a balance sheet or in the related notes to the consolidated financial statements prepared in accordance with
GAAP, which are, individually or in the aggregate, material to the business, results of operations, financial condition or prospects
of the Company and its subsidiaries taken as a whole except (i) liabilities reflected in the Seller Disclosure Letter, or (ii)
liabilities of the Company or its subsidiaries incurred thereby following the date hereof in the ordinary course of business.
(b)
Except as stated in the Seller SEC Reports, the Company and its subsidiaries maintain a system of internal accounting controls
sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or
specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity
with United States generally accepted accounting principles and to maintain asset accountability, (iii) access to assets is permitted
only in accordance with management’s general or specific authorization, and (iv) the recorded accountability for assets
is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.
Except as stated in the Seller SEC Reports, the and its subsidiaries have established disclosure controls and procedures and designed
such disclosure controls and procedures to ensure that material information relating thereto, including the its subsidiaries,
is made known to the executive officers and directors of the Company by others within those entities. The Seller has made available
to the Buyers copies of, all written descriptions of, and all policies, manuals and other documents promulgating, such disclosure
controls and procedures. The books, records and accounts of the Company and its subsidiaries accurately and fairly reflect, in
reasonable detail, the transactions in, and dispositions of, the assets of, and the results of operations of, the Company and
its subsidiaries all to the extent required by generally accepted accounting principles.
4.9
Absence of Certain Changes or Events. Since the date of the last filed Seller SEC Report, there has not been: (i) any Material
Adverse Effect on the Company or any of its subsidiaries, (ii) any declaration, setting aside or payment of any dividend on, or
other distribution (whether in cash, stock or property) in respect of, any of the Company’s or any of its subsidiaries’
capital stock, or any purchase, redemption or other acquisition by Seller or the Company of any of the Company’s capital
stock or any other securities of the Company or its subsidiaries or any options, warrants, calls or rights to acquire any such
shares or other securities, (iii) any split, combination or reclassification of any of the Company’s or any of its subsidiaries’
capital stock, (iv) any granting by the Company or any of its subsidiaries of any increase in compensation or fringe benefits,
except for normal increases of cash compensation in the ordinary course of business consistent with past practice, or any payment
by the Company or any of its subsidiaries of any bonus, except for bonuses made in the ordinary course of business consistent
with past practice, or any granting by the Company or any of its subsidiaries of any increase in severance or termination pay
or any entry by the Company or any of its subsidiaries into any currently effective employment, severance, termination or indemnification
agreement or any agreement the benefits of which are contingent or the terms of which are materially altered upon the occurrence
of a transaction involving Seller of the nature contemplated hereby, (v) entry by the Company or any of its subsidiaries into
any sale, licensing or other agreement with regard to the acquisition or disposition of any Intellectual Property (as defined
in Section 4.18 hereof) or other property thereof, other than licenses in the ordinary course of business consistent with
past practice, and other than any licenses disclosed on Section 4.18(j) of the Seller Disclosure Letter, (vi) any material
change by the Company in its accounting methods, principles or practices, except as required by concurrent changes in GAAP, (vii)
any revaluation by the Company or any of its subsidiaries of any of its or their assets, including, without limitation, writing
down the value of capitalized inventory or writing off notes or accounts receivable, or (viii) any sale of assets of the Company
or its subsidiaries other than in the ordinary course of business.
4.10
Absence of Litigation. Except as set forth in Section 4.10 of the Seller Disclosure Letter, there are no claims,
actions, suits or proceedings pending or, to the knowledge of Seller, threatened (or, to the knowledge of Seller, any governmental
or regulatory investigation pending or threatened) against the Company or any of its subsidiaries or any properties or rights
of the Company or any of its subsidiaries, before any Governmental Entity.
4.11
Employee Benefit Plans.
(a)
Neither the Company nor any of its subsidiaries has at any time ever maintained, established, sponsored, participated in, or contributed
to, any employee compensation, incentive, fringe or benefit plans, programs, policies, commitments or other arrangements (whether
or not set forth in a written document and including, without limitation, all “employee benefit plans” (within the
meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”)) covering
(i) any active or former employee, director or consultant of the Company, (ii) any subsidiary of the Company, or (iii) any trade
or business (whether or not incorporated) which is a member of a controlled group or which is under common control with the Company
within the meaning of Section 414 of the Internal Revenue Code of 1986, as amended (the “Code”), or with respect
to which the Company or any of its subsidiaries has or, to Seller’s knowledge, may in the future have liability.
(b)
Neither the Company nor any of its subsidiaries has at any time ever maintained, established, sponsored, participated in, or contributed
to any plan subject to Title IV of ERISA or Section 412 of the Code and at no time has Seller or any of its subsidiaries contributed
to or been requested to contribute to any “multiemployer plan,” as such term is defined in ERISA or to any plan described
in Section 413(c) of the Code. Neither the Company, any of its subsidiaries, nor any officer or director of the Company or any
of its subsidiaries is subject to any liability or penalty under Section 4975 through 4980B of the Code or Title I of ERISA. There
are no audits, inquiries or proceedings pending or, to the knowledge of Seller, threatened by the Internal Revenue Service or
Department of Labor with respect to any employee benefit plan of the Company or any of its subsidiaries.
(c)
Neither the Company nor any of its subsidiaries has in any material respect, violated any of the health continuation requirements
of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the requirements of Family
Medical Leave Act of 1993, as amended, the requirements of the Women’s Health and Cancer Rights Act, as amended, the requirements
of the Newborns’ and Mothers’ Health Protection Act of 1996, as amended, or any similar provisions of state law applicable
to employees of the Company or any of its subsidiaries.
(d)
Except as otherwise provided in the Termination Agreement, neither the execution and delivery of this Agreement nor the consummation
of the transactions contemplated hereby will result in any payment (including severance, unemployment compensation, golden parachute,
bonus or otherwise) becoming due to any stockholder, director or employee of the Company or any of its subsidiaries.
4.12
Labor Matters. (i) There are no controversies pending or, to the knowledge of Seller, threatened, between the Company or
any of its subsidiaries and any of their respective employees; (ii) as of the date of this Agreement, neither the Company nor
any of its subsidiaries is a party to any collective bargaining agreement or other labor union contract applicable to persons
employed by the Company or its subsidiaries nor does the Company or its subsidiaries know of any activities or proceedings of
any labor union to organize any such employees; and (iii) as of the date of this Agreement, neither the Company nor any of its
subsidiaries has any knowledge of any strikes, slowdowns, work stoppages or lockouts, or threats thereof, by or with respect to
any employees of the Company or any of its subsidiaries. There is no pending or, to the knowledge of Seller, threatened labor
dispute involving the Company or any of its subsidiaries and any group of its employees nor has the Company or any of its subsidiaries
experienced any labor interruptions over the past three (3) years, and the Company and its subsidiaries consider their relationships
with their employees to be good. The Company and its subsidiaries are in compliance in all material respects with all applicable
foreign, federal, state and local laws, rules and regulations regarding employment, employment practices, terms and conditions
of employment and wages and hours.
4.13
Restrictions on Business Activities. There is no agreement, commitment, judgment, injunction, order or decree binding upon
the Company or any of its subsidiaries or to which the Company or any of its subsidiaries is a party or any of its subsidiaries
which has or could reasonably be expected to have the effect, in any material respect, of prohibiting or impairing any present
business practice of the Company or any of its subsidiaries, any acquisition of property by the Company or any of its subsidiaries
or the conduct of business by the Company or any of its subsidiaries as currently conducted.
4.14
Title to Property. Except as set forth on Section 4.14 of the Seller Disclosure Letter, neither the Company nor
any of its subsidiaries owns any material real property. Except as set forth on Section 4.14 of the Seller Disclosure Letter,
the Company and each of its subsidiaries have good and defensible title to all of their material real and personal properties
and assets, free and clear of all liens, charges and encumbrances except liens for taxes not yet due and payable and such liens
or other imperfections of title, if any, as do not materially detract from the value of or interfere with the present use of the
property affected thereby; and all leases pursuant to which the Company or any of its subsidiaries lease from others material
amounts of real or personal property are in good standing, valid and effective in accordance with their respective terms, and
there is not, under any of such leases, any existing material default or event of default (or any event which with notice or lapse
of time, or both, would constitute a material default and in respect of which the Company or subsidiary has not taken adequate
steps to prevent such default from occurring). All the plants, structures and equipment owned by or being acquired under a capital
lease by the Company and its subsidiaries, except such as may be under construction, are in good operating condition and repair,
in all material respects, subject to normal wear and tear.
4.15
Taxes.
(a)
Definition of Taxes. For all purposes of and under this Agreement, “Tax” or “Taxes”
refers to any and all federal, state, local and foreign taxes, assessments and other governmental charges, duties, impositions
and liabilities relating to taxes, including taxes based upon or measured by gross receipts, income, profits, sales, use and occupation,
and value added, ad valorem, transfer, franchise, withholding, payroll, recapture, employment, excise and property taxes, together
with all interest, penalties and additions imposed with respect to such amounts and any obligations under any agreements or arrangements
with any other person with respect to such amounts and including any liability for taxes of a predecessor entity.
(b)
Tax Returns and Audits.
(i)
The Company and each of its subsidiaries have timely filed all federal, state, local and foreign returns, estimates, information
statements and reports (“Company Returns”) relating to Taxes required to be filed by the Company and each of
its subsidiaries with any Tax authority, except such Returns which are not material to the Company or which are for taxes being
contested. Such Company Returns are true and correct in all material respects, have been completed in accordance with applicable
law, and all Taxes shown to be due on such Company Returns have been paid. There are no liens for Taxes (other than Taxes not
yet due and payable) upon any assets of the Company or any of its subsidiaries.
(ii)
The Company and each of its subsidiaries as of the Closing Date will have withheld with respect to its employees all federal and
state income taxes, Taxes pursuant to the Federal Insurance Contribution Act (“FICA”), Taxes pursuant to the
Federal Unemployment Tax Act (“FUTA”) and other Taxes required to be withheld.
(iii)
Neither the Company nor any of its subsidiaries has been delinquent in the payment of any material Tax nor is there any material
Tax deficiency outstanding, proposed or assessed against the Company or any of its subsidiaries, nor has the Company or any of
its subsidiaries executed any unexpired waiver of any statute of limitations on or extending the period for the assessment or
collection of any Tax.
(iv)
No audit or other examination of any Company Return by any Tax authority is presently in progress, nor has the Seller, the Company
or any of its subsidiaries been notified of any request for such an audit or other examination.
(v)
No adjustment relating to any Company Returns filed by the Company or any of its subsidiaries has been proposed in writing formally
or informally by any Tax authority to the Company or any of its subsidiaries or any representative thereof.
(vi)
Neither the Company nor any of its subsidiaries has any liability for any unpaid Taxes, contingent or otherwise, which could be
deemed to be material to the Company or its subsidiaries, other than any liability for unpaid Taxes that may have accrued since
the date of the latest financial statements of the Seller included in the Seller SEC Reports in connection with the operation
of the business of the Company and its subsidiaries in the ordinary course.
(vii)
There is no contract, agreement, plan or arrangement to which the Company or any of its subsidiaries is a party as of the date
of this Agreement, including but not limited to the provisions of this Agreement, covering any employee or former employee of
the Company or any of its subsidiaries that, individually or collectively, would reasonably be expected to give rise to the payment
of any amount that would not be deductible pursuant to Sections 280G, 404 or 162(m) of the Code. There is no contract, agreement,
plan or arrangement to which Seller is a party or by which it is bound to compensate any individual for excise taxes paid pursuant
to Section 4999 of the Code.
(viii)
Neither the Company nor any of its subsidiaries has filed any consent agreement under Section 341(f) of the Code or agreed to
have Section 341(f)(2) of the Code apply to any disposition of a subsection (f) asset (as defined in Section 341(f)(4) of the
Code) owned by the Company or any of its subsidiaries.
(ix)
Neither the Company nor any of its subsidiaries is party to or has any obligation under any tax-sharing, tax indemnity or tax
allocation agreement or arrangement.
(x)
None of the Company’s or its subsidiaries’ assets are tax exempt use property within the meaning of Section 168(h)
of the Code.
(xi)
Neither the Company nor any subsidiary of the Company has participated as either a “distributing corporation” or a
“controlled corporation” in a distribution of stock qualifying for tax-free treatment under Section 355 of the Code.
4.16
Environmental Matters. Except as set forth on Section 4.16 of the Seller Disclosure Letter, the operations of the
Company and each of its subsidiaries are and have been in compliance in all material respects with all applicable Environmental
Laws (as defined below), which compliance includes obtaining, maintaining in good standing and complying in all material respects
with all Environmental Permits (as defined below) and no action or proceeding is pending or threatened to revoke, modify or terminate
any such Environmental Permit, and, to the knowledge of Seller, no facts, circumstances or conditions currently exist that could
adversely affect such continued compliance with Environmental Laws and Environmental Permits or require currently unbudgeted capital
expenditures to achieve or maintain such continued compliance with Environmental Laws and Environmental Permits.
“Environmental
Law” means any law, as now or hereafter in effect, in any way relating to the protection of human health and safety,
the environment or natural resources including the Comprehensive Environmental Response, Compensation and Liability Act (42 U.S.C.
§ 9601 et seq. ), the Hazardous Materials Transportation Act (49 U.S.C. App. § 1801 et seq. ), the Resource
Conservation and Recovery Act (42 U.S.C. § 6901 et seq. ), the Clean Water Act (33 U.S.C. § 1251 et seq.
), the Clean Air Act (42 U.S.C. § 7401 et seq. ) the Toxic Substances Control Act (15 U.S.C. § 2601 et seq.
), the Federal Insecticide, Fungicide, and Rodenticide Act (7 U.S.C. § 136 et seq. ), and the Occupational Safety
and Health Act (29 U.S.C. § 651 et seq. ), as each has been or may be amended and the regulations promulgated pursuant
thereto.
“Environmental
Permit” means any permit required by Environmental Laws for the operation of such company.
4.17
Brokers. Seller has not incurred, nor will it incur, directly or indirectly, any liability for brokerage or finders fees
or agent’s commissions or any similar charges in connection with this Agreement or any transaction contemplated hereby.
4.18
Intellectual Property.
(a)
For the purposes of this Agreement, the following terms have the following definitions:
(i)
“Intellectual Property” means any or all of the following and all rights in, arising out of, or associated
therewith: (i) all United States, international and foreign patents and applications therefor and all reissues, divisions, renewals,
extensions, provisionals, continuations and continuations-in-part thereof; (ii) all inventions (whether patentable or not), invention
disclosures, improvements, trade secrets, proprietary information, know how, technology, technical data and customer lists, and
all documentation relating to any of the foregoing; (iii) all copyrights, copyrights registrations and applications therefor,
and all other rights corresponding thereto throughout the world; (iv) all mask works, mask work registrations and applications
therefor, and any equivalent or similar rights in semiconductor masks, layouts, architectures or topology; (v) domain names, uniform
resource locators and other names and locators associated with the Internet, (vi) all computer software, including all source
code, object code, firmware, development tools, files, records and data, and all media on which any of the foregoing is recorded;
(vii) all industrial designs and any registrations and applications therefor throughout the world; (viii) all trade names, logos,
common law trademarks and service marks, trademark and service mark registrations and applications therefor throughout the world;
(ix) all databases and data collections and all rights therein throughout the world; (x) all moral and economic rights of authors
and inventors, however denominated, throughout the world, and (xi) any similar or equivalent rights to any of the foregoing anywhere
in the world.
(ii)
“Company Intellectual Property” shall mean any Intellectual Property that is owned by, or exclusively licensed
to, the Company or any of its subsidiaries.
(iii)
“Registered Intellectual Property” means all United States, international and foreign: (i) patents and patent
applications (including provisional applications); (ii) registered trademarks, applications to register trademarks, intent-to-use
applications, or other registrations or applications related to trademarks; (iii) registered copyrights and applications for copyright
registration; and (iv) any other Intellectual Property that is the subject of an application, certificate, filing, registration
or other document issued, filed with, or recorded by any state, government or other public legal authority.
(iv)
“Company Registered Intellectual Property” means all of the Registered Intellectual Property owned by, or filed
in the name of, the Company or any of its subsidiaries.
(b)
Section 4.18(b) of the Seller Disclosure Letter contains a complete and accurate list of (i) all Company Registered Intellectual
Property and specifies, where applicable, the jurisdictions in which each such item of Company Registered Intellectual Property
has been issued or registered, and (ii) all proceedings or actions before any court or tribunal (including the United States Patent
and Trademark Office (the “PTO”) or equivalent authority anywhere else in the world) related to any of Company
Registered Intellectual Property.
(c)
Section 4.18(c) of the Seller Disclosure Letter contains a complete and accurate list (by name and version number) of all
products, software or service offerings of the Company or any of its subsidiaries (collectively, “Company Products”)
that have been sold, distributed or otherwise disposed of in the five (5)-year period preceding the date hereof or which the Company
or any of its subsidiaries currently intends to sell, distribute or otherwise dispose of in the future, including any products
or service offerings under development.
(d)
No Company Intellectual Property or Company Product is subject to any proceeding or outstanding decree, order, judgment, contract,
license, agreement, or stipulation restricting in any manner the use, transfer, or licensing thereof by the Company or any of
its subsidiaries, or which may affect the validity, use or enforceability of such Company Intellectual Property or Company Product.
(e)
Each item of Company Registered Intellectual Property is valid and existing, all necessary registration, maintenance and renewal
fees currently due in connection with such Company Registered Intellectual Property have been made and all necessary documents,
recordations and certificates in connection with such Company Registered Intellectual Property have been filed with the relevant
patent, copyright, trademark or other authorities in the United States or foreign jurisdictions, as the case may be, for the purposes
of prosecuting, maintaining or perfecting such Company Registered Intellectual Property.
(f)
Section 4.18(f) of the Seller Disclosure Letter contains a complete and accurate list of all actions that are required
to be taken by the Company within ninety (90) days of the date hereof with respect to any of Company Registered Intellectual Property.
(g)
The Company owns and has good and exclusive title to each item of Company Intellectual Property owned by it, free and clear of
any lien or encumbrance (excluding non-exclusive licenses and related restrictions granted in the ordinary course). Without limiting
the generality of the foregoing, (i) to the knowledge of Seller, the Company or its subsidiaries are the exclusive owner of all
trademarks and trade names used in connection with the operation or conduct of the business of the Company and its subsidiaries,
including the sale, distribution or provision of any Company Products by the Company or any of its subsidiaries , (ii) the Company
or its subsidiaries own exclusively, and have good title to, all copyrighted works that are included or incorporated into Company
Products or which the Company or any of its subsidiaries otherwise purports to own, and (iii) to the knowledge of the Seller,
the manufacture, sale or use of Company Products does not infringe any patents.
(h)
To the extent that any technology, software or Intellectual Property has been developed or created independently or jointly by
a third party for the Company or any of its subsidiaries, or is incorporated into any of Company Products, the Company and its
subsidiaries have a written agreement with such third party with respect thereto and the Company and its subsidiaries thereby
either (i) have obtained ownership of, and are the exclusive owner of, or (ii) have obtained perpetual, irrevocable, worldwide
non-terminable licenses (sufficient for the conduct of its business as currently conducted and as proposed to be conducted) to
all such third party’s Intellectual Property in such work, material or invention by operation of law or by valid assignment
or license, to the fullest extent it is legally possible to do so.
(i)
Neither the Company nor any of its subsidiaries has transferred ownership of, or granted any exclusive license with respect to,
any Intellectual Property that is or was Company Intellectual Property, to any third party, or knowingly permitted the Company’s
rights in such Company Intellectual Property to lapse or enter the public domain other than for trademarks for Company Products
no longer sold by the Company for which the Company has let the applicable trademark rights become abandoned in the Company’s
ordinary course of business.
(j)
Other than “shrink wrapped” and similar widely available commercial end-user licenses, Section 4.18(j) of the
Seller Disclosure Letter contains a complete and accurate list of all contracts, licenses and agreements to which the Company
or any of its subsidiaries is a party (i) with respect to Company Intellectual Property licensed or transferred to any third party,
or (ii) pursuant to which a third party has licensed or transferred any material Intellectual Property to the Company or any of
its subsidiaries.
(k)
All contracts, licenses and agreements relating to either (i) Company Intellectual Property or (ii) Intellectual Property of a
third party licensed to the Company or any of its subsidiaries, are, to the knowledge of Seller, in full force and effect. The
consummation of the transactions contemplated by this Agreement and the Termination Agreement will neither violate nor result
in the breach, modification, cancellation, termination, suspension of, or acceleration of any payments with respect to, such contracts,
licenses and agreements. Each of the Company and its subsidiaries is in compliance with, and has not breached any term of any
such contracts, licenses and agreements and, to the knowledge of Seller, all other parties to such contracts, licenses and agreements
are in compliance with, and have not breached any term of, such contracts, licenses and agreements. Following the Closing Date,
the Buyers will be permitted to exercise all of the Company’s and its subsidiaries’ rights under such contracts, licenses
and agreements to the same extent the Company and its subsidiaries would have been able to had the transactions contemplated by
this Agreement not occurred and without the payment of any additional amounts or consideration other than ongoing fees, royalties
or payments which the Company or any of its subsidiaries would otherwise be required to pay. Following the Closing Date, the Buyers
will be permitted to exercise all of the Company’s and its subsidiaries’ rights under such contracts, licenses and
agreements to the same extent as the Company and its subsidiaries would have been able to had the transactions contemplated by
this Agreement not occurred and without being required to pay any additional amounts or consideration other than fees, royalties
or payments which the Company or its subsidiaries would otherwise be required to pay had such transactions contemplated hereby
not occurred.
(l)
The operation of the business of the Company and its subsidiaries as such business currently is conducted, including (i) the Company’s
and its subsidiaries’ design, development, manufacture, distribution, reproduction, marketing or sale of the products, software
or services of the Company and its subsidiaries (including Company Products), and (ii) the Company’s use of any product,
device or process, to the knowledge of Seller, has not, does not and will not infringe or misappropriate the Intellectual Property
of any third party or, to its knowledge, constitute unfair competition or trade practices under the laws of any jurisdiction.
(m)
Company Intellectual Property constitutes all the Intellectual Property owned by the Company or exclusively licensed to the Company
and used in and/or necessary to the conduct of the business of the Company and its subsidiaries as it currently is conducted,
and as it is currently planned or contemplated to be conducted by the Company and its subsidiaries, including, without limitation,
the design, development, manufacture, use, import and sale of products, technology and performance of services (including Company
Products).
(n)
Neither the Company nor any of its subsidiaries has received notice from any third party that the operation of the business of
the Company or any of its subsidiaries or any act, product or service of the Company or any of its subsidiaries, infringes or
misappropriates the Intellectual Property of any third party or constitutes unfair competition or trade practices under the laws
of any jurisdiction.
(o)
To the knowledge of Seller, no person has or is infringing or misappropriating any Company Intellectual Property.
(p)
The Company and each of its subsidiaries has taken reasonable steps to protect the Company’s and its subsidiaries’
rights in the Company’s confidential information and trade secrets that it wishes to protect or any trade secrets or confidential
information of third parties provided to the Company or any of its subsidiaries, and, without limiting the foregoing, each of
the Company and its subsidiaries has and enforces a policy requiring each employee and contractor to execute a proprietary information/confidentiality
agreement substantially in the form provided to the Buyers and all current and former employees and contractors of the Company
and any of its subsidiaries have executed such an agreement, except where the failure to do so is not reasonably expected to be
material to the Company.
4.19
Agreements, Contracts and Commitments.
(a)
Except as set forth on Section 4.19(a) of the Seller Disclosure Letter, neither the Company nor any of its subsidiaries
is a party to or is bound by:
(i)
any employment or consulting agreement, contract or commitment with any officer or director or higher level employee or member
of the Company’s Board of Directors, other than those that are terminable by the Company or any of its subsidiaries on no
more than thirty (30) days’ notice without liability or financial obligation to the Company;
(ii)
any agreement or plan, including, without limitation, any stock option plan, stock appreciation right plan or stock purchase plan,
any of the benefits of which will be increased, or the vesting of benefits of which will be accelerated, by the occurrence of
any of the transactions contemplated by this Agreement or the Termination Agreement or the value of any of the benefits of which
will be calculated on the basis of any of the transactions contemplated by this Agreement or the Termination Agreement;
(iii)
any agreement of indemnification or any guaranty other than any agreement of indemnification entered into in connection with the
sale, license, distribution, reselling or other transfer of software products in the ordinary course of business or in connection
with the provision of services in the ordinary course of business;
(iv)
any agreement, contract or commitment containing any covenant limiting in any respect the right of the Company or any of its subsidiaries
to engage in any line of business presently conducted by the Company or any subsidiary, or to compete with any person or granting
any exclusive distribution rights;
(v)
any agreement, contract or commitment currently in force relating to the disposition or acquisition by the Company or any of its
subsidiaries after the date of this Agreement of a material amount of assets not in the ordinary course of business or pursuant
to which the Company or any of its subsidiaries has any material ownership interest in any corporation, partnership, joint venture
or other business enterprise other than the Company’s subsidiaries;
(vi)
any dealer, distributor, joint marketing or development agreement currently in force under which the Company or any of its subsidiaries
have continuing material obligations to jointly market any product, technology or service and which may not be canceled without
penalty upon notice of sixty (60) days or less, or any material agreement pursuant to which the Company or any of its subsidiaries
have continuing material obligations to jointly develop any intellectual property that will not be owned, in whole or in part,
by Seller or any of its subsidiaries and which may not be canceled without penalty upon notice of sixty (60) days or less;
(vii)
any agreement, contract or commitment currently in force to provide source code to any third party for any product or technology
that is material to the Company and its subsidiaries taken as a whole;
(viii)
any agreement, contract or commitment currently in force to license any third party to manufacture or reproduce any Company Products,
service or technology or any agreement, contract or commitment currently in force to sell or distribute any Company Products,
services or technology, except agreements with distributors or sales representative in the normal course of business cancelable
without penalty upon written notice of ninety (90) days or less;
(ix)
any mortgages, indentures, guarantees, loans or credit agreements, security agreements or other agreements or instruments relating
to the borrowing of money or extension of credit;
(x)
any material settlement agreement entered into within three (3) years prior to the date of this Agreement; or
(xi)
any other material agreement, contract or commitment currently in force that is outside the ordinary course of business or that
has a value of $50,000 or more within a twelve (12) month period in any individual case.
(b)
Neither the Company nor any of its subsidiaries, nor to Seller’s knowledge any other party to a Company Contract (as defined
below), is in breach, violation or default under, and neither the Company nor any of its subsidiaries has received written notice
that it has breached, violated or defaulted under, any of the terms or conditions of any of the agreements, contracts or commitments
to which the Company or any of its subsidiaries is a party or by which it is bound that are required to be set forth in the Seller
Disclosure Letter (any such agreement, contract or commitment, a “Company Contract”) in such a manner as would
permit any other party to cancel or terminate any such Company Contract, or would permit any other party to seek material damages
or other remedies (for any or all of such breaches, violations or defaults, in the aggregate).
4.20
Insurance. The Company maintains insurance policies and fidelity bonds covering the assets, business, equipment, properties,
operations, employees, officers and directors of the Company and its subsidiaries (collectively, the “Insurance Policies”)
which are of the type and in amounts customarily carried by persons conducting businesses similar to those of the Company and
its subsidiaries. There is no material claim by the Company or any of its subsidiaries pending under any of the Insurance Policies
as to which coverage has been questioned, denied or disputed by the underwriters of such policies or bonds. The Company is not
aware of, and has not received notice under any Insurance Policies of, (i) an insurer’s intention or threat to cancel or
terminate any of the Insurance Policies, (ii) an insurer’s intention or threat to increase the premiums due under any of
the Insurance Policies.
4.21
Board Approval. The Board of Directors of Seller has, as of the date of this Agreement, (i) approved this Agreement and
the transactions contemplated hereby, subject to stockholder approval, (ii) determined that the Sale is fair to and in the best
interests of the stockholders of Seller, and (iii) recommended that the stockholders of Seller approve and adopt this Agreement
and approve the Sale.
4.22
Political Contributions; Foreign Corrupt Practices Act.
(a)
Neither the Company nor any of the any subsidiary thereof has, and no person or entity acting on behalf or at the request of the
Company or any of its subsidiaries has, at any time during the last five years (i) made any unlawful contribution to any candidate
for foreign office or failed to disclose fully any contribution in violation of law, or (ii) made any payment to any federal or
state governmental officer or official, or other person charged with similar public or quasi-public duties, other than payments
required or permitted by the laws of the United States or any other applicable jurisdiction.
(b)
No officer, director or affiliate of the Company or any of the subsidiaries thereof, has been, within the five years ending on
the Closing Date, a party to any bankruptcy petition against such person or against any business of which such person was affiliated;
convicted in a criminal proceeding or subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);
subject to any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction,
permanently or temporarily enjoining, barring, suspending or otherwise limiting their involvement in any type of business, securities
or banking activities; or found by a court of competent jurisdiction in a civil action, by the SEC or the Commodity Futures Trading
Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended
or vacated.
(c)
Neither the Company or any of subsidiaries thereof, nor, to the best knowledge of the Seller, any director, officer, agent, employee,
or other person associated with, or acting on behalf of, the Company or any of the subsidiaries thereof, has, directly or indirectly:
used any corporate funds for unlawful contributions, gifts, entertainment, or other unlawful expenses relating to political activity;
made any unlawful payment to foreign or domestic government officials or employees or to foreign or domestic political parties
or campaigns from corporate funds; violated any provision of the Foreign Corrupt Practices Act of 1977, as amended; or made any
bribe, rebate, payoff, influence payment, kickback, or other unlawful payment. The Company’s internal accounting controls
and procedures are sufficient to cause the Company and each subsidiaries thereof to comply in all respects with the Foreign Corrupt
Practices Act of 1977, as amended.
4.23
Vote Required. The affirmative vote of the holders of a majority of the outstanding shares of Seller’s common stock,
$.0001 par value (“Seller Common Stock”) and Series C Preferred Stock, is the only vote of the holders of any
class or series of Seller’s capital stock necessary to approve and adopt this Agreement and approve the Sale.
ARTICLE
V
BUYER
REPRESENTATIONS AND WARRANTIES.
Each
Buyer, severally, but not jointly, hereby represents and warrants to Seller, as of the date hereof and as of the Closing Date
as though made at the Closing Date, subject to such exceptions as are specifically disclosed in writing (with reference to the
specific sections of this Agreement to which each such exception applies; provided, however, that
if any section of the Buyer Disclosure Letter, as defined below, discloses an item or information in such a way as to make its
relevance to the disclosure required by another section reasonably apparent based upon the substance of such disclosure, the matter
shall be deemed to have been disclosed in such other section of the Buyer Disclosure Letter, notwithstanding the omission of an
appropriate cross-reference to such other section) in the disclosure letter supplied by the Buyers to Seller, dated as of the
date hereof (the “Buyer Disclosure Letter”), as follows:
5.1
Authority Relative to this Agreement.
(a)
Such Buyer has all necessary power and authority to execute and deliver this Agreement, and to perform its obligations hereunder
and thereunder, to consummate the transactions contemplated hereby and thereby. The execution and delivery of this Agreement by
such Buyer and the consummation by such Buyer of the transactions contemplated hereby and thereby have been duly and validly authorized
by all necessary action on the part of such Buyer and no other proceedings on the part of such Buyer are necessary to authorize
this Agreement or to consummate the transactions so contemplated. This Agreement have been duly and validly executed and delivered
by such Buyer and, assuming the due authorization, execution and delivery by Seller, constitute legal and binding obligations
of such Buyer, enforceable against such Buyer in accordance with their respective terms.
(b)
Each Buyer is an individual who has reached the age majority in his state of residence and has all necessary requisite power and
authority, and all necessary consents, authorizations, approvals, orders, licenses, certificates, and permits of and from, and
declarations and filings with, all federal, state, local, and other governmental authorities and all courts and other tribunals,
to own, lease, license, and use his properties and assets and to carry on the business in which he is now engaged and the businesses
in which he contemplates engaging.
5.2
No Conflict; Required Filings and Consents.
(a)
The execution and delivery of this Agreement by such Buyer does not, and the performance of this Agreement by such Buyer will
not, to the best of such Buyer’s knowledge, conflict with or violate any law, rule, regulation, order, judgment or decree
applicable to such Buyer or by which his respective properties are bound or affected, or result in any breach of or constitute
a default (or an event that with notice or lapse of time or both would become a default) under, or impair such Buyer’s or
any such subsidiary’s rights or alter the rights or obligations of any third party under, or give to others any rights of
termination, amendment, acceleration or cancellation of, or result in the creation of a lien or encumbrance on any of the properties
or assets of such Buyer or any of its subsidiaries pursuant to, any material note, bond, mortgage, indenture, contract, agreement,
lease, license, permit, franchise or other instrument or obligation to which such Buyer is a party or by which such Buyer or its
or any of his respective properties are bound or affected.
(b)
The execution and delivery of this Agreement by such Buyer does not, and the performance of this Agreement by such Buyer will
not, require any consent, approval, authorization or permit of, or registration, filing with or notification to, any Governmental
Entity, except for (i) applicable requirements, if any, of applicable Federal and state securities laws, and foreign Governmental
Entities and the rules and regulations promulgated thereunder, and where the failure to obtain such consents, approvals, authorizations
or permits, or to make such filings or notifications, (i) would not prevent consummation of the Sale or otherwise prevent such
Buyer from performing his obligations under this Agreement, or (B) could not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect on such Buyer or the Buyers taken as a whole.
5.3
Information Statement. None of the information supplied or to be supplied by such Buyer for inclusion or incorporation
by reference in Seller’s Information Statement on Form 14C relating to the Sale will, on the date the Information Statement
is mailed to the stockholders of Seller and as of the date of the Sale, contain any untrue statement of a material fact or omit
to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the
circumstances under which they are made, not misleading.
5.4
Brokers. Such Buyer has not incurred, nor will it incur, directly or indirectly, any liability for brokerage or finders
fees or agent’s commissions or any similar charges in connection with this Agreement or any transaction contemplated hereby.
5.5
Investment Representations. Such Buyer is an “accredited investor” as such term is defined in Rule 501 of Regulation
D promulgated under the Securities Act, as well as a sophisticated investor. Such is purchasing the Shares for its own account,
for investment purposes only and has no current arrangements or understandings for the resale or distribution to others and has
no present intent of distributing or reselling the Shares acquired thereby in violation of the Securities Act or any applicable
state securities law. Such Buyer acknowledges that the offer and sale of the Shares have not been registered under the Securities
Act or the securities laws of any state or other jurisdiction, and that the Shares are being offered and sold pursuant to an exemption
from registration contained in the Securities Act, and cannot be disposed of unless they are subsequently registered under the
Securities Act and any applicable state laws or an exemption from such registration is available. Such Buyer understands and agrees
that the Shares will bear a legend substantially similar to the legend set forth below in addition to any other legend that may
be required by applicable law:
THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE
SECURITIES LAWS. THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE DISPOSED OF EXCEPT (A) PURSUANT TO AN EFFECTIVE REGISTRATION
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS, OR (B) IN A TRANSACTION WHICH IS EXEMPT FROM
REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS, AS EVIDENCED BY A LEGAL OPINION
OF COUNSEL REASONABLY ACCEPTABLE TO THE COMPANY TO SUCH EFFECT.
5.6
Patriot Act Compliance. Such Buyer hereby represents and warrants that such Buyer is not, nor is it acting as an agent,
representative, intermediary or nominee for, a person identified on the list of blocked persons maintained by the Office of Foreign
Assets Control, U.S. Department of Treasury.
5.7
Access to Information. By virtue of such Buyer’s position, he has access to the same kind of information which would
be available in a registration statement filed under the Securities Act.
ARTICLE
VI
CONDUCT
PRIOR TO THE CLOSING
6.1
Conduct of Business by Seller.
(a)
During the period commencing with the execution and delivery of this Agreement and continuing until the earlier to occur of the
termination of this Agreement pursuant to its terms or the Closing Date, the Seller, the Company, and each of their respective
subsidiaries shall, except to the extent that the other parties shall otherwise consent in writing, carry on its business, in
the usual, regular and ordinary course, in substantially the same manner as heretofore conducted and in compliance with all applicable
laws and regulations, pay its debts and taxes when due subject to good faith disputes over such debts or taxes, pay or perform
other material obligations when due, and use its commercially reasonable efforts consistent with past practices and policies to
(i) preserve intact its present business organization, (ii) keep available the services of its present officers and employees
and (iii) preserve its relationships with customers, suppliers, distributors, licensors, licensees, and others with which it has
business dealings. In addition, the parties will promptly notify each other of any material event involving its business or operations.
(b)
Except as permitted or required by the terms of this Agreement, during the period commencing with the execution and delivery of
this Agreement and continuing until the earlier of the termination of this Agreement pursuant to its terms or the Closing Date,
Seller shall not do any of the following, and shall not permit any of its subsidiaries to do any of the following, except to the
extent that the other party shall otherwise consent in writing:
(i)
purchase, redeem or otherwise acquire, directly or indirectly, any shares of capital stock, except repurchases of unvested shares
at cost in connection with the termination of the employment relationship with any employee pursuant to stock option or purchase
agreements in effect on the date hereof;
(ii)
acquire or agree to acquire by merging or consolidating with, or by purchasing any equity interest in or a portion of the assets
of, or by any other manner, any business or any corporation, limited liability company, general or limited partnership, business
trust, unincorporated association or other business organization, entity or division thereof, or otherwise acquire or agree to
acquire all or substantially all of the assets of any of the foregoing, or enter into any joint ventures, strategic partnerships
or similar alliances;
(iii)
incur or enter into any agreement, contract or other commitment or arrangement requiring such party or any of its subsidiaries
to make payments in excess of $50,000 in any individual case, or $100,000 in the aggregate;
(v)
engage in any action with the intent to, directly or indirectly, adversely impact or materially delay the consummation of the
Sale or any of the other transactions contemplated by this Agreement; or
(vi)
agree in writing or otherwise to take any of the actions described in Section 6.1(b)(i) through Section 6.1(b)(v) ,
inclusive.
(c)
Notwithstanding anything contained in this Article VI, it is expressly agreed and understood that any action which might
otherwise fall within the description of Section 6.1(a) or 6.1(b), but which could not be reasonably expected to materially affect
the business, operations or value of such party, shall not be prohibited by Article VI; provided, however,
that prompt notice of any such actions shall be provided by the party taking such action to the other.
ARTICLE
VII
ADDITIONAL
AGREEMENTS
7.1
Information Statement. As promptly as practicable after the execution of this Agreement, Seller shall take all action necessary
in accordance with Nevada Law, its Articles of Incorporation and Bylaws and the Exchange Act to solicit a majority of the stockholders
of Seller to act by written consent to approve this Agreement and the Sale. Thereafter, Seller shall as promptly as practicable
prepare and file with the SEC an information statement to be delivered to the stockholders of Seller in connection with the Sale
(the “Information Statement”). Each Buyer shall promptly provide to Seller all information concerning its business
and financial statements and affairs as reasonably may be required or appropriate for inclusion in the Information Statement,
or in any amendments or supplements thereto, and to cause its counsel and auditors to cooperate with Seller’s counsel and
auditors in the preparation of the Information Statement. Seller shall promptly respond to any comments of the SEC, and shall
use its best reasonable efforts to have the Information Statement cleared by the SEC as promptly as practicable after such filing.
Seller shall cause the Information Statement to be mailed to its stockholders at the earliest practicable time after it is cleared
by the SEC. As promptly as practicable after the date of this Agreement, Seller and each Buyer shall prepare and file any other
filings required to be filed by it under the Exchange Act, the Securities Act or any other Federal, foreign, state “blue
sky” or related laws relating to the Sale and the transactions contemplated by this Agreement (the “Other Filings”).
Seller shall promptly supply upon the receipt of any comments from the SEC or its staff or any other government officials and
of any request by the SEC or its staff or any other government officials for amendments or supplements to the Information Statement
or any Other Filing, or for additional information and shall supply the other with copies of all correspondence between such party
or any of its representatives, on the one hand, and the SEC or its staff or any other government officials, on the other hand,
with respect to the Information Statement, the Sale or any Other Filing. Seller and each Buyer shall cause all documents that
it is responsible for filing with the SEC or other regulatory authorities under this Section 7.1(a) to comply in all material
respects with all applicable requirements of law and the rules and regulations promulgated thereunder. Whenever any event occurs
that is required to be set forth in an amendment or supplement to the Information Statement or any Other Filing, Seller or any
Buyer, as the case may be, shall promptly inform the other of such occurrence and cooperate in filing with the SEC or its staff
or any other government officials, and/or mailing to the stockholders of Seller and any Buyer, such amendment or supplement.
7.2
Access to Information. During the period commencing with the execution and delivery of this Agreement until the earlier
to occur of the termination of this Agreement pursuant to its terms and the Closing Date, Seller shall afford each Buyer and its
and the Company’s accountants, counsel and other representatives reasonable access during normal business hours to the properties,
books, records and personnel of Seller to obtain all information concerning the business of the Company and its subsidiaries,
including, without limitation, the status of its product development efforts, properties, results of operations and personnel,
as any Buyer may reasonably request. No information or knowledge obtained by any Buyer during the course of any investigation
conducted pursuant to this Section 7.5 shall affect, or be deemed to modify in any respect any representation or warranty
contained herein or the conditions to the obligations of the parties to consummate the Sale contained herein.
7.3
No Solicitation.
(a)
During the period commencing with the execution and delivery of this Agreement until the earlier to occur of the termination of
this Agreement pursuant to its terms and the Closing Date, Seller, the Company, and their respective subsidiaries shall not, nor
will they authorize any of their respective officers, directors, affiliates or employees or any investment banker, attorney or
other advisor or representative retained by any of them to, directly or indirectly, (i) solicit, initiate, encourage or induce
the making, submission or announcement of any Acquisition Proposal (as defined in Section 7.3(b) hereof), (ii) participate
in any discussions or negotiations regarding, or furnish to any person any information with respect to, or take any other action
to facilitate any inquiries or the making of any proposal that constitutes or may reasonably be expected to lead to, any Acquisition
Proposal, (iii) engage in discussions or negotiations with any person with respect to any Acquisition Proposal, except as to the
existence of these provisions, (iv) approve, endorse or recommend any Acquisition Proposal, or (v) enter into any letter of intent
or similar document or any contract agreement or commitment contemplating or otherwise relating to any Acquisition Proposal.
(b)
For all purposes of and under this Agreement, the term “Acquisition Proposal” shall mean any transaction or
series of related transactions, other than the transactions contemplated by this Agreement, involving (i) any acquisition or purchase
from Seller by any person or “group” (as defined under Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder) of more than a twenty-five percent (25%) interest in the total outstanding voting securities of Seller
or any of its subsidiaries, or any tender offer or exchange offer that if consummated would result in any person or “group”
(as defined under Section 13(d) of the Exchange Act and the rules and regulations thereunder) beneficially owning five percent
(5%) or more of the total outstanding voting securities of Seller or any of its subsidiaries, or any sale, consolidation, business
combination or similar transaction involving Seller pursuant to which the stockholders of Seller immediately preceding such transaction
would hold less than ninety five percent (95%) of the equity interests in the surviving or resulting entity of such transaction;
(ii) any sale, lease (other than in the ordinary course of business), exchange, transfer, license (other than in the ordinary
course of business), acquisition or disposition of more than five percent (5%) of the assets of Seller; (iii) any liquidation
or dissolution of Seller; or (iv) any sale, lease (other than in the ordinary course of business), exchange, transfer, license
(other than in the ordinary course of business), acquisition or disposition of any of the assets or securities of Seller.
(c)
In addition to the obligations of Seller set forth in Section 7.3(a) hereof, Seller shall advise the Buyers, as promptly
as practicable, and in any event within twenty-four (24) hours, orally, of (i) any request for information which Seller reasonably
believes could lead to an Acquisition Proposal or, (ii) any Acquisition Proposal, or (iii) any inquiry with respect to or which
Seller reasonably should believe could lead to any Acquisition Proposal, the (iv) material terms and conditions of any such request,
Acquisition Proposal or inquiry, and (v) the identity of the person or group making any such request, Acquisition Proposal or
inquiry. Seller shall keep the Buyers informed in all material respects of the status and details (including material amendments
or proposed amendments) of any such request, Acquisition Proposal or inquiry.
7.4
Public Disclosure. The Buyers and the Seller shall consult with each other, and to the extent practicable, agree, before
issuing any press release or otherwise making any public statement with respect to this Agreement, the Sale or an Acquisition
Proposal, and shall not issue any such press release or make any such public statement prior to such consultation, except as may
be required by applicable law or any listing agreement with a national securities exchange. The parties hereto have agreed to
the text of the joint press release announcing the signing of this Agreement.
7.5
Reasonable Efforts; Notification.
(a)
Upon the terms and subject to the conditions set forth in this Agreement, each of the parties hereto shall use its commercially
reasonable best efforts to take, or cause to be taken, all actions, and to do, or cause to be done, and to assist and cooperate
with the other parties hereto in doing, all things necessary, proper or advisable to consummate and make effective, in the most
expeditious manner practicable, the Sale and the other transactions contemplated by this Agreement, including, without limitation,
using reasonable efforts to accomplish the following: (i) the taking of all reasonable actions necessary to cause the conditions
precedent set forth in Article VI hereof to be satisfied, (ii) the obtaining of all necessary actions or nonactions, waivers,
consents, approvals, orders and authorizations from Governmental Entities, and the making of all necessary registrations, declarations
and filings (including registrations, declarations and filings with Governmental Entities, if any), and the taking of all reasonable
steps as may be necessary to avoid any suit, claim, action, investigation or proceeding by any Governmental Entity, (iii) the
obtaining of all necessary consents, approvals or waivers from third parties which may be required or desirable as a result of,
or in connection with, the transactions contemplated by this Agreement, (iv) the defending of any suits, claims, actions, investigations
or proceedings, whether judicial or administrative, challenging this Agreement or the consummation of the transactions contemplated
hereby, including, without limitation, seeking to have any stay or temporary restraining order entered by any court or other Governmental
Entity vacated or reversed, and (v) the execution or delivery of any additional certificates, instruments and other documents
necessary to consummate the transactions contemplated by, and to fully carry out the purposes of, this Agreement. In connection
with and without limiting the foregoing, each Buyer and the Seller and its Board of Directors shall, if any state takeover statute
or similar statute or regulation is or becomes applicable to the Sale, this Agreement or any of the transactions contemplated
by this Agreement, use all commercially reasonable efforts to ensure that the Sale and the other transactions contemplated by
this Agreement may be consummated as promptly as practicable on the terms contemplated by this Agreement and otherwise to minimize
the effect of such statute or regulation on the Sale, this Agreement and the transactions contemplated hereby. Notwithstanding
anything to the contrary in this Agreement, nothing in this Agreement shall be deemed to require any Buyer or the Seller or any
subsidiary or affiliate thereof to agree to any divestiture by itself or any of its affiliates of shares of capital stock or of
any business, assets or property, or the imposition of any material limitation on the ability of any of them to conduct their
businesses or to own or exercise control of such assets, properties and stock.
(b)
Seller shall give prompt notice to the Buyers upon becoming aware that any representation or warranty made by Seller in this Agreement
has become untrue or inaccurate, or that Seller has failed to comply with or satisfy in any material respect any covenant, condition
or agreement to be complied with or satisfied by it under this Agreement, in each case, such that the conditions set forth in
Section 8.3(a) or Section 8.3(b) hereof would not be satisfied, provided, however, that no
such notification shall affect the representations, warranties, covenants or agreements of Seller, or the conditions to the obligations
of the parties under this Agreement.
(c)
Such Buyer shall give prompt notice to Seller upon becoming aware that any representation or warranty made by such Buyer in this
Agreement has become untrue or inaccurate, or that such Buyer has failed to comply with or satisfy in any material respect any
covenant, condition or agreement to be complied with or satisfied by it under this Agreement, in each case, such that the conditions
set forth in Section 8.2(a) or Section 8.2(b) hereof would not be satisfied, provided, however,
that no such notification shall affect the representations, warranties, covenants or agreements of such Buyer, or the conditions
to the obligations of the parties under this Agreement.
7.6
Third Party Consents. As soon as practicable following the date hereof, each Buyer and the Seller shall each use its respective
commercially reasonable best efforts to obtain any consents, waivers and approvals under any of its or its subsidiaries’
respective agreements, contracts, licenses or leases required to be obtained in connection with the consummation of the transactions
contemplated hereby.
ARTICLE
VIII
CONDITIONS
TO THE SALE
8.1
Conditions to Obligations of Each Party to Effect the Sale. The respective obligations of each party to this Agreement
to effect the Sale shall be subject to the satisfaction or fulfillment, at or prior to the Closing Date, of the following conditions:
(a)
Stockholder Approval. This Agreement shall have been duly approved and adopted, and the Sale shall have been duly approved,
by the requisite vote under Nevada Law, by the stockholders of Seller.
(b)
Pricing Analysis. Seller shall have obtained a Broker Opinion of Value through Pricing Analysis from an independent firm.
(c)
Information Statement Cleared. Seller shall have cleared all comments from the SEC with respect to the Information Statement,
the Information Statement shall have been mailed by Seller to its stockholders, and in accordance with the Exchange Act, twenty
(20) days shall have elapsed since such mailing date. All Other Filings shall have been approved or declared effective and no
stop order shall have been issued and no proceeding shall have been initiated to revoke any such approval or effectiveness.
(d)
No Order. No Governmental Entity shall have enacted, issued, promulgated, enforced or entered any statute, rule, regulation,
executive order, decree, injunction or other order (whether temporary, preliminary or permanent) which is in effect and which
has the effect of making the Sale illegal or otherwise prohibiting consummation of the Sale.
8.2
Additional Conditions to Obligations of Seller. The obligation of Seller to consummate and effect the Sale shall be subject
to the satisfaction or fulfillment, at or prior to the Closing Date, of each of the following conditions, any of which may be
waived, in writing, exclusively by Seller:
(a)
Representations and Warranties. Each representation and warranty of Buyer contained in this Agreement (i) shall have been
true and correct in all material respects as of the date of this Agreement and (ii) shall be true and correct in all material
respects on and as of the Closing Date with the same force and effect as if made on the Closing Date, except for those representations
and warranties which address matters only as of a particular date, which representations and warranties shall have been true and
correct in all material respects as of such particular date; provided, however, that in all cases
where a representation or warranty contains a materiality or Material Adverse Effect qualifier, such representation or warranty
shall be true and correct in all respects as of the dates set forth above. Seller shall have received a certificate with respect
to the foregoing signed on behalf of each Buyer by duly authorized officer thereof.
(b)
Agreements and Covenants. Each Buyer shall have performed or complied in all material respects with all agreements and
covenants required by this Agreement to be performed or complied with by them on or prior to the Closing Date, and Seller shall
have received a certificate to such effect signed on behalf of the Buyers by a duly authorized officer thereof.
(c)
Material Adverse Effect. No Material Adverse Effect with respect to the Buyers shall have occurred since the date of this
Agreement.
8.3
Additional Conditions to the Obligations of Buyer. The obligations of Buyer to consummate and effect the Sale shall be
subject to the satisfaction or fulfillment, at or prior to the Closing Date, of each of the following conditions, any of which
may be waived, in writing, exclusively by Buyer:
(a)
Representations and Warranties. Each representation and warranty of Seller contained in this Agreement (i) shall have been
true and correct in all material respects as of the date of this Agreement and (ii) shall be true and correct in all material
respects on and as of the Closing Date with the same force and effect as if made on the Closing Date, except for those representations
and warranties which address matters only as of a particular date, which representations and warranties shall have been true and
correct in all material respects as of such particular date; provided, however, that in all cases
where a representation or warranty contains a materiality or Material Adverse Effect qualifier, such representation or warranty
shall be true and correct in all respects as of the dates set forth above. Buyer shall have received a certificate with respect
to the foregoing signed on behalf of Seller by a duly authorized officer thereof.
(b)
Agreements and Covenants. Seller shall have performed or complied in all material respects with all agreements and covenants
required by this Agreement to be performed or complied with by it at or prior to the Closing Date, and Buyer shall have received
a certificate to such effect signed on behalf of Seller by a duly authorized officer thereof.
(c)
Material Adverse Effect. No Material Adverse Effect with respect to Seller and its subsidiaries shall have occurred since
the date of this Agreement.
(d)
Unconditional Releases. Upon the Closing Date and after Buyer delivers its shares for cancellation, the Seller shall execute
and deliver to each Buyer a full and unconditional release in the form of Exhibit
8.2(d) hereto.
(e)
Termination Agreement. The Seller and Wais Asefi shall have entered into the Termination Agreement.
(f)
Voting Agreement. Each officer and director of Seller and each Buyer shall have entered into a voting agreement, pursuant
to which they shall agree to vote in favor of the transactions contemplated by this Agreement and the Termination Agreement.
ARTICLE
IX
TERMINATION,
AMENDMENT AND WAIVER
9.1
Termination. This Agreement may be terminated at any time prior to the Closing Date, whether before or after the requisite
approval of the stockholders of Seller has been obtained in respect of this Agreement and the Sale:
(a)
by mutual written consent of the Buyers and the Seller, duly authorized by the Board of Directors of the Seller;
(b)
by either the Buyers or Seller if the Sale shall not have been consummated by the date that is two (2) months following the date
of this Agreement for any reason; provided, however, that the right to terminate this Agreement under
this Section 9.1(b) shall not be available to any party whose action or failure to act has been a principal cause of or
resulted in the failure of the Sale to occur on or before such date, and such action or failure to act constitutes a breach of
this Agreement;
(c)
by either the Buyers or Seller if a Governmental Entity shall have issued an order, decree or ruling or taken any other action,
in any case having the effect of permanently restraining, enjoining or otherwise prohibiting the Sale, which order, decree, ruling
or other action is final and nonappealable;
(d)
by either the Buyers or Seller if the requisite approval of the stockholders of Seller contemplated by this Agreement shall not
have been obtained by reason of the failure to obtain the requisite vote at a meeting of the stockholders of Seller, duly convened
therefor or at any adjournment or postponement thereof; provided, however, that the right to terminate
this Agreement under this Section 9.1(d) shall not be available to Seller in the event that the failure to obtain the requisite
approval of the stockholders of Seller shall have been caused by the action or failure to act of Seller, and such action or failure
to act constitutes a breach of Section 8.1 of this Agreement;
(e)
by Seller, upon a breach of any representation, warranty, covenant or agreement on the part of Buyer set forth in this Agreement,
or if any representation or warranty of Buyer shall have become untrue, in either case such that the conditions set forth in Section
8.2(a) or Section 8.2(b) hereof would not be satisfied as of the time of such breach or as of the time such representation
or warranty shall have become untrue; provided, however, that if such inaccuracy in Buyer’s
representations and warranties or breach by Buyer is curable by Buyer through the exercise of its commercially reasonable efforts,
then Seller may not terminate this Agreement under this Section 9.1(e) for fifteen (15) calendar days following the delivery
of written notice from Seller to Buyer of such breach, provided Buyer continues to exercise commercially reasonable efforts to
cure such breach (it being understood that Seller may not terminate this Agreement pursuant to this Section 9.1(e) if such
breach by Buyer is cured during such thirty (30) calendar day period);
(f)
by Buyer, upon a breach of any representation, warranty, covenant or agreement on the part of Seller set forth in this Agreement,
or if any representation or warranty of Seller shall have become untrue, in either case such that the conditions set forth in
Section 8.3(a) or Section 8.3(b) hereof would not be satisfied as of the time of such breach or as of the time such
representation or warranty shall have become untrue; provided, however, that if such inaccuracy in
Seller’s representations and warranties or breach by Seller is curable by Seller through the exercise of its commercially
reasonable efforts, then Buyer may not terminate this Agreement under this Section 9.1(f) for fifteen (15) calendar days
following the delivery of written notice from Buyer to Seller of such breach, provided Seller continues to exercise commercially
reasonable efforts to cure such breach (it being understood that Buyer may not terminate this Agreement pursuant to this Section
9.1(f) if such breach by Seller is cured during such thirty (30) calendar day period); or
(g)
by Seller if a Material Adverse Effect with respect to the Buyer shall have occurred since the date of this Agreement; provided,
however, that if such Material Adverse Effect with respect to the Buyer is curable by Buyer through the exercise
of its commercially reasonable efforts, then Seller may not terminate this Agreement under this Section 9.1(h) for fifteen
(15) calendar days following the occurrence of such Material Adverse Effect, provided Buyer continues to exercise commercially
reasonable efforts to cure such Material Adverse Effect (it being understood that Seller may not terminate this Agreement pursuant
to this Section 9.1(h) if such Material Adverse Effect is cured during such thirty (30) calendar day period.
9.2
Notice of Termination; Effect of Termination. Any termination of this Agreement pursuant to Section 9.1 hereof shall
be effective immediately upon the delivery of written notice of the terminating party to the other party or parties hereto. In
the event of the termination of this Agreement pursuant to Section 9.1 hereof, this Agreement shall be of no further force
or effect, except (i) as set forth in this Section 9.2, and as set forth in Section 9.3 and Article X (General
Provisions) hereof, each of which shall survive the termination of this Agreement, and (ii) nothing herein shall relieve any party
hereto from any liability for any willful breach of this Agreement.
9.3
Fees and Expenses. Except as otherwise provided in this Section 9.3, all fees and expenses incurred in connection
with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such fees and expenses, whether
or not the Sale is consummated.
9.4
Amendment. Subject to applicable law, this Agreement may be amended by the parties hereto at any time by execution of an
instrument in writing, signed on behalf of each of the parties hereto by a duly authorized officer thereof.
9.5
Extension; Waiver. At any time prior to the Closing Date, any party hereto may, to the extent legally allowed, (i) extend
the time for the performance of any of the obligations or other acts of the other parties hereto, (ii) waive any inaccuracies
in the representations and warranties made to such party contained herein or in any document delivered pursuant hereto, and (iii)
waive compliance with any of the agreements or conditions for the benefit of such party contained herein. Any agreement on the
part of a party hereto to any such extension or waiver shall be valid only if set forth in an instrument in writing signed on
behalf of such party. Any delay in exercising any right under this Agreement shall not constitute a waiver of such right.
ARTICLE
IX
INDEMNIFICATION
10.1
Indemnification.
(a)
By Seller. Subject to the other terms and conditions of this Article X, Seller hereby agrees to indemnify and hold
harmless each Buyer and its employees, counsel, agents, and stockholders, in each case past, present, or as they may exist at
any time after the date of this Agreement, and each person, if any, who controls, controlled, or will control any of them within
the meaning of Section 15 of the Securities Act or Section 20(a) of the Exchange Act (each a “Buyer Indemnified Party”)
against any and all losses, liabilities, damages, and expenses whatsoever (which shall include, for all purposes of this Section
7.7, but not be limited to, counsel fees and any and all expenses whatsoever incurred in investigating, preparing, or defending
against any litigation, commenced or threatened, or any claim whatsoever, and any and all amounts paid in settlement of any claim
or litigation) (“Claims”) as and when incurred arising out of, based upon, or in connection with (a) any breach
of any representation, warranty, covenant, or agreement of Seller contained in this Agreement, (b) if the Closing takes place,
any act or alleged omission occurring at or prior to the Closing (including without limitation any which arise out of, are based
upon, or are in connection with any of the transactions contemplated hereby) which subjects any Buyer to damages related to the
intentional act or intentional omission, (c) the products and operations of the Company, if any, prior to Closing, and (d) the
existence of actual, contingent, or potential undisclosed liabilities of the Company and the subsidiaries thereof. The foregoing
agreement to indemnify shall be in addition to any liability Seller may otherwise have, including liabilities arising under this
Agreement.
(b)
By Buyer. Subject to the other terms and conditions of this Article X, Buyer shall indemnify and hold harmless Seller
and its officers, directors and stockholders (each an “Seller Indemnified Party”), from and against any and
all Claims suffered by such Seller Indemnified Party resulting from or arising out of any: (i) inaccuracy in or breach of any
of the representations or warranties made by Buyer in this Agreement; or (ii) breach or nonfulfillment of any covenants or agreements
made by Buyer in this Agreement.
10.2
Indemnification Procedures for Third-Party Claims. In making a claim under this Article X, the party making a claim
is referred to as the “Indemnified Party,” and the party against whom such claims are asserted is referred
to as the “Indemnifying Party.”.
(a)
Upon obtaining knowledge of any Claim by a third party that has given rise to, or is expected to give rise to, a claim for indemnification
hereunder, the Indemnified Party shall give prompt written notice (“Notice of Claim”) of such claim or demand
to the Indemnifying Party, specifying in reasonable detail such information as the Indemnified Party may have with respect to
such indemnification claim (including copies of any summons, complaint or other pleading that may have been served on it and any
written claim, demand, invoice, billing or other document evidencing or asserting the same). Subject to the limitations set forth
in Section 10.2 hereof, no failure or delay by an Indemnified Party in the performance of the foregoing shall reduce or
otherwise affect the obligation of the Indemnifying Party to indemnify and hold the Indemnified Party harmless, except to the
extent that such failure or delay shall have actually materially adversely affected the Indemnifying Party’s ability to
defend against, settle or satisfy any Claims for which the Indemnified Party is entitled to indemnification hereunder.
(b)
If the claim or demand set forth in the Notice of Claim given by an Indemnified Party pursuant to Section 10.2(a) hereof
is a claim or demand asserted by a third party, the Indemnifying Party shall have fifteen (15) Business Days after the date on
which the Notice of Claim is delivered to notify the Indemnified Party in writing of its election to defend such third party claim
or demand on behalf of the Indemnified Party. If the Indemnifying Party elects to defend such third party claim or demand, the
Indemnified Party shall make available to the Indemnifying Party and its agents and representatives all records and other materials
that are reasonably required in the defense of such third party claim or demand and shall otherwise cooperate with, and assist
the Indemnifying Party in the defense of, such third party claim or demand, and so long as the Indemnifying Party is defending
such third party claim in good faith, the Indemnified Party shall not pay, settle or compromise such third party claim or demand.
If the Indemnifying Party elects to defend such third party claim or demand the Indemnified Party shall have the right to participate
in the defense of such third party claim or demand at the Indemnified Party’s expense. In the event, however,
that such Indemnified Party reasonably determines that representation by counsel to the Indemnifying Party of both the Indemnifying
Party and such Indemnified Party could reasonably be expected to present counsel with a conflict of interest, then the Indemnified
Party may employ separate counsel to represent or defend it in any such action or proceeding and the Indemnifying Party shall
be liable for the reasonable fees and expenses of such counsel. If the Indemnifying Party does not elect to defend such third
party claim or demand or does not defend such third party claim or demand in good faith, the Indemnified Party shall have the
right, in addition to any other right or remedy it may have hereunder, at the Indemnifying Party’s expense, to defend such
third party claim or demand; provided, however, that: (i) such Indemnified Party shall not have any
obligation to participate in the defense of or defend any such third party claim or demand; (ii) such Indemnified Party’s
defense of or its participation in the defense of any such third party claim or demand shall not in any way diminish or lessen
the obligations of the Indemnifying Party under the agreements of indemnification set forth in this Article X; and (iii)
such Indemnified Party may not settle any claim without the consent of the Indemnifying Party, which consent shall not be unreasonably
withheld or delayed.
(c)
Except for third party claims being defended in good faith, the Indemnifying Party shall satisfy its obligations under this Article
X in respect of a valid claim for indemnification hereunder that is not contested by the Indemnified Party in good faith by
wire transfer of immediately available funds to the Indemnified Party within thirty (30) days after the date on which Notice of
Claim is delivered to the Indemnified Party.
10.3
Indemnification Procedures for Non-Third Party Claims. In the event any Indemnified Party should have an indemnification
claim against the Indemnifying Party under this Agreement that does not involve a claim by a third party, the Indemnified Party
shall promptly deliver notice of such claim to the Indemnifying Party in writing and in reasonable detail and shall cooperate
with, answers questions and make available to the Indemnifying Party the information relied upon by the Indemnified Party to substantiate
the claim. The failure by any Indemnified Party to so notify the Indemnifying Party shall not relieve the Indemnifying Party from
any liability that it may have to such Indemnified Party, except to the extent that Indemnifying Party have been actually materially
prejudiced by such failure. If the Indemnifying Party does not notify the Indemnified Party within fifteen (15) Business Days
following its receipt of such notice that the Indemnifying Party dispute such claim, such claim specified by the Indemnified Party
in such notice shall be conclusively deemed a liability of the Indemnifying Party under this Article X and the Indemnifying
Party shall pay the amount of such liability to the Indemnified Party on demand, or in the case of any notice in which the amount
of the claim is estimated, on such later date when the amount of such claim is finally determined. If the Indemnifying Party disputes
its liability with respect to such Claim in a timely manner, the Indemnifying Party and the Indemnified Party shall proceed in
good faith to negotiate a resolution of such dispute and, if not resolved through negotiations, such dispute shall be submitted
to a court of law.
10.4
Damages. Notwithstanding anything to the contrary in this Agreement, neither party shall be liable to the other for any
consequential, indirect, exemplary or punitive damages.
10.5
Release from Claim. The Indemnifying Party shall not, without the prior written consent of the Indemnified Party, effect any settlement
of any pending or threatened Claim in respect of which any Indemnified Party is or could have been a party and indemnification
could have been sought hereunder by such Indemnified Party, unless such settlement includes an unconditional release of such Indemnified
Party from all liability on claims that are the subject matter of such indemnification.
ARTICLE
XI
GENERAL
PROVISIONS
11.1
Representations and Warranties. The representations and warranties of Seller and Buyer contained in this Agreement shall
survive the Closing for a period of two (2) years.
11.2
Notices. All notices and other communications hereunder shall be in writing and shall be deemed given if delivered personally
or by commercial delivery service, or sent via telecopy (receipt confirmed) to the parties at the following addresses or telecopy
numbers (or at such other address or telecopy numbers for a party as shall be specified by like notice):
(a)
if to the Buyers, to:
WAIS
ASEFI
1940
Contra Costa Blvd.
Pleasant
Hill, CA 94523
(b)
if to Seller, to:
RESONATE
BLENDS, INC.
Attn:
Geoffrey Selzer, CEO
26565
Agoura Road, Suite 200
Calabasas,
CA 91302
11.3
Interpretation; Knowledge.
(a)
When a reference is made in this Agreement to exhibits, such reference shall be to an exhibit to this Agreement unless otherwise
indicated. When a reference is made in this Agreement to sections, such reference shall be to a section of this Agreement. Unless
otherwise indicated the words “include,” “includes” and “including” when used herein shall
be deemed in each case to be followed by the words “without limitation.” The table of contents and headings contained
in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement.
When reference is made herein to “the business of” an entity, such reference shall be deemed to include the business
of all direct and indirect subsidiaries of such entity. Reference to the subsidiaries of an entity shall be deemed to include
all direct and indirect subsidiaries of such entity.
(b)
For purposes of this Agreement the term “knowledge” means with respect to a party hereto, with respect to any
matter in question, that any of the executive officers of such party has actual knowledge of such matter or knowledge that such
individual could reasonably be expected to obtain upon reasonable investigation or inquiry into such matter.
(c)
For purposes of this Agreement, the term “Material Adverse Effect” when used in connection with an entity means
any change, event, violation, inaccuracy, circumstance or effect that is materially adverse to the business, assets (including
intangible assets), prospects, capitalization, financial condition or results of operations of such entity and its subsidiaries
taken as a whole. For purposes of this Agreement, the term “person” shall mean any individual, corporation
(including any non-profit corporation), general partnership, limited partnership, limited liability partnership, joint venture,
estate, trust, company (including any limited liability company or joint stock company), firm or other enterprise, association,
organization, entity or Governmental Entity.
11.4
Counterparts. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the
same agreement and shall become effective when one or more counterparts have been signed by each of the parties and delivered
to the other party, it being understood that all parties need not sign the same counterpart.
11.5
Entire Agreement; Third Party Beneficiaries. This Agreement and the documents and instruments and other agreements among
the parties hereto as contemplated by or referred to herein, including the Seller Disclosure Letter and the Buyer Disclosure Letter
(i) constitute the entire agreement among the parties with respect to the subject matter hereof and supersede all prior agreements
and understandings, both written and oral, among the parties with respect to the subject matter hereof; and (ii) are not intended
to confer upon any other person any rights or remedies hereunder.
11.6
Severability. In the event that any provision of this Agreement or the application thereof, becomes or is declared by a
court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement will continue in full force
and effect and the application of such provision to other persons or circumstances will be interpreted so as reasonably to effect
the intent of the parties hereto. The parties further agree to replace such void or unenforceable provision of this Agreement
with a valid and enforceable provision that will achieve, to the extent possible, the economic, business and other purposes of
such void or unenforceable provision.
11.7
Other Remedies; Specific Performance. Except as otherwise provided herein, any and all remedies herein expressly conferred
upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such
party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy. The parties hereto agree
that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance
with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to seek an injunction
or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in any court
of the United States or any state having jurisdiction, this being in addition to any other remedy to which they are entitled at
law or in equity.
11.8
Governing Law. This Agreement, and all claims or causes of action (whether at law, in contract or in tort) that may be
based upon, arise out of or relate to this Agreement or the negotiation, execution or performance hereof, shall be governed by
and construed in accordance with the laws of the State of Nevada, without giving effect to any choice or conflict of law provision
or rule (whether of the State of Nevada or any other jurisdiction) that would cause the application of the laws of any jurisdiction
other than the State of Nevada. Each of the parties hereto (i) consents to submit itself to the personal jurisdiction of the District
Court of the State of Nevada in the event any dispute arises out of this Agreement or any of the transactions contemplated hereby,
and, in connection with any such matter, to service of process by notice as otherwise provided herein, (ii) agrees that it will
not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court and (iii) agrees
that it will not bring any action relating to this Agreement or any of the transactions contemplated hereby in any court other
than the District Court of the State of Nevada. Any party may make service on another party by sending or delivering a copy of
the process to the party to be served at the address and in the manner provided for the giving of notices in Section 11.2.
11.9
Rules of Construction. The parties hereto agree that they have been represented by counsel during the negotiation and execution
of this Agreement and, therefore, waive the application of any law, regulation, holding or rule of construction providing that
ambiguities in an agreement or other document will be construed against the party drafting such agreement or document.
11.10
Assignment. No party may assign either this Agreement or any of its rights, interests, or obligations hereunder without
the prior written approval of the other parties. Subject to the preceding sentence, this Agreement shall be binding upon and shall
inure to the benefit of the parties hereto and their respective successors and permitted assigns.
11.11
WAIVER OF JURY TRIAL. EACH OF BUYER AND SELLER HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING
OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE ACTIONS OF
BUYER OR SELLER IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT HEREOF.
[
Remainder of Page Intentionally Left Blank ]
IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first above written.
SELLER
|
|
|
|
|
Resonate
Blends, Inc.
|
|
|
|
|
|
By:
|
Geoffrey
Selzer
|
|
Its:
|
CEO
|
|
|
|
BUYERS:
|
|
|
|
|
|
Wais
Asefi
|
|
|
|
|
|
Nick
Miniello
|
|
|
|
|
|
Juleon
Asefi
|
|
|
|
|
|
Curt
Byers
|
|
Annex
A
Textmunication,
Inc. Shares to Buyers
Shareholder
|
Number
of Shares
|
Wais
Asefi
|
|
Nick
Miniello
|
|
Juleon
Asefi
|
|
Curt
Byers
|
|
Annex
B
Pricing
analysis of TransWorld Business Advisors
Annex
C
Amendment
to Articles of Incorporation
Section
1. Authorized Shares. The aggregate number of shares which the Corporation shall have authority to issue is two hundred and ten
million (210,000,000) shares, consisting of two classes to be designated, respectively, “Common Stock” and “Preferred
Stock,” with all of such shares having a par value of $.0001 per share. The total number of shares of Common Stock that
the Corporation shall have authority to issue is two hundred million (200,000,000) shares. The total number of shares of Preferred
Stock that the Corporation shall have authority to issue is ten million (10,000,000) shares. The Preferred Stock may be issued
in one or more series, each series to be appropriately designated by a distinguishing letter or title, prior to the issuance of
any shares thereof. The voting powers, designations, preferences, limitations, restrictions, and relative, participating, optional
and other rights, and the qualifications, limitations, or restrictions thereof, of the Preferred Stock shall hereinafter be prescribed
by resolution of the board of directors pursuant to Section 3 of this Article III.
Resonate Blends (PK) (USOTC:KOAN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Resonate Blends (PK) (USOTC:KOAN)
Historical Stock Chart
From Sep 2023 to Sep 2024